pamidronate and zoledronic acid

pamidronate has been researched along with zoledronic acid in 324 studies

Research

Studies (324)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	7 (2.16)	18.2507
2000's	183 (56.48)	29.6817
2010's	118 (36.42)	24.3611
2020's	16 (4.94)	2.80

Authors

Authors	Studies
Martin, MB; Oldfield, E; Szabo, CM	1
Bachmann, R; Bisping, M; Born, AR; Cortesi, R; Glatt, M; Green, JR; Guiglia, G; Jaeggi, KA; Jeker, H; Klein, R; Müller, K; Ramseier, U; Schmid, J; Schreiber, G; Seltenmeyer, Y; Widler, L	1
Bruchhaus, I; Chan, JM; Croft, SL; Flessner, RM; Ghosh, S; Kemp, RG; Kendrick, H; Kobayashi, S; Lea, CR; Lewis, JC; Loftus, TC; Meints, GA; Nozaki, T; Oldfield, E; Tovian, ZS	1
Chan, JM; Flessner, R; Gómez, AO; González-Pacanowska, D; Jennings, S; Kosztowski, T; Kotsikorou, E; Meints, GA; Morita, CT; Odeh, S; Oldfield, E; Papapoulos, SE; Raker, AM; Sanders, JM; Schwerdtfeger, C; Song, Y; van Beek, ER; Wang, H; Zhang, Y	1
Araujo, FG; Chan, JM; Ling, Y; Moreno, SN; Odeh, S; Oldfield, E; Sahota, G	1
Haase, C; Koscielski, LA; Leon, A; Oldfield, E; Song, Y; Studer, D; Zhang, Y	1
Hall, P; Hudock, MP; Leon, A; Liu, L; Morita, CT; Oldfield, E; Puan, KJ; Studer, D; Yang, Y; Yin, F	1
Barnett, BL; Dunford, JE; Ebetino, FH; Kavanagh, KL; Kwaasi, AA; Oppermann, U; Rogers, MJ; Russell, RG	1
Lombardo, F; Obach, RS; Waters, NJ	1
Axelson, J; Cao, R; Chang, SC; Chang, TH; Guo, RT; Hudock, MP; K-M Chen, C; Ko, TP; Kumar, A; Liang, PH; No, JH; Oldfield, E; Song, Y; Wang, AH; Zhang, Y	1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ	1
Berlicki, Ł; Kafarski, P; Mucha, A	1
Avnet, S; Bianchini, G; Chiminazzo, A; Di Pompo, G; Granchi, D; Michelin, RA; Minto, A; Scarso, A; Sgarbossa, P; Strukul, G	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Artyushin, OI; Brel, VK; Chuprov-Netochin, RN; Leonov, SV; Semenov, VV; Semenova, MN	1
Almeida Paz, FA; Barbosa, JS; Braga, SS	1
Braidman, IP; Evans, CE	1
Delmas, PD; Lipton, A	1
Green, J	1
Burckhardt, P; Green, JR; Ibarra de Palacios, P; Kandra, A; Leuenberger, P; Sauty, A; Sitzler, L; Thiébaud, D; Zieschang, J	1
Green, JR; Jee, WS; Li, QN; Ma, YF; Müller, K; Pataki, A	1
Aparicio, A; Berenson, J; Gardner, A; Lichtenstein, A; Savage, A; Tu, Y	1
Berenson, J; Hortobagyi, G; Lipton, A; Major, PP	1
Amiot, M; Barillé, S; Bataille, R; Berthaud, P; Collette, M; Derenne, S; Harousseau, JL; Robillard, N	1
Arnett, TR; Colston, KW; Mansi, JL; Pirianov, G; Senaratne, SG	1
Body, JJ	2
Getz, B; Ingle, JN; Pederson, L; Reinholz, GG; Sanders, ES; Spelsberg, TC; Subramaniam, M	1
Possinger, K	1
Body, JJ; Fromigue, O; Lagneaux, L	1
Coleman, RE	4
Abdi, E; Bell, R; Body, J; Hon, J; Lortholary, A; Major, P; Menssen, HD; Mills, G; Quebe-Fehling, E; Seaman, J; Yunus, F	1
Berenson, JR; Coleman, RE; Dreicer, R; Howell, A; Kuross, SA; Lipton, A; Morley, W; Porter, L; Rosen, LS; Seaman, JJ	1
Fong, EM; Guenette, RS; Lee, MV; Singer, FR	1
Ali, SM; Costa, L; Esteva, FJ; Harvey, H; Hortobagyi, G; Knight, R; Lipton, A; Seaman, J	1
Lortholary, A	1
Cooke-Yarborough, C; Little, DG; Smith, NC; Williams, PR	1
Bajwa, K; DesHarnais Castel, L; Markle, JP; Schulman, KA; Timbie, JW; Zacker, C	1
Hussein, MA; Juturi, JV; Lieberman, I	1
Barlogie, B; Choi, Y; Epstein, J; Johnson, CL; Pearse, RN; Yaccoby, S	1
Blaschke, S; Emons, G; Frosch, KH; Gründker, C; Hofbauer, LC; Lauck, V; Viereck, V	1
Mykała-Cieśla, J; Stajszczyk, M	1
Body, JJ; Fromigué, O	1
Bellahcène, A; Bonjean, K; Castronovo, V; Devy, L; Foidart, JM; Green, JR; Ruetz, S; Wood, J	1
Anderson, K; Berenson, JR; Biermann, JS; Hillner, BE; Kyle, RA; Lipton, A; Yee, GC	1
Culligan, DJ; Gordon, S; Greaves, M; Helfrich, MH; Ralston, SH; Rogers, MJ; Sati, HI; Soutar, RL	1
Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M	1
Bowes, M; Chan, O; Fox, AJ; Glatt, M; Green, J; Kesingland, A; Kidd, BL; McNair, K; Medhurst, SJ; Patel, S; Urban, LA; Walker, K	1
Major, P	1
Berenson, JR	4
Lipton, A	4
Cook, R; Major, PP	1
Enjo, F; Kimura, S; Kobayashi, Y; Kuroda, J; Maekawa, T; Ottmann, OG; Segawa, H; Tokuda, H; Ueda, T; Urasaki, Y; Yoshikawa, T	1
Clarke, IA; Colston, KW; Kirby, RS; Oades, GM; Senaratne, SG	1
Saad, F	1
Marx, RE	1
Apffelstaedt, J; Belch, A; Chen, BL; Coleman, RE; Gordon, D; Howell, A; Hussein, MA; Kaminski, M; Mackey, J; Reitsma, DJ; Rosen, LS; Seaman, JJ	1
Csermak, K; Tarassoff, P	1
Adami, S; Crepaldi, G; Filipponi, P; Sartori, L	1
Chen, BL; Coleman, RE; Dugan, W; Eisenberg, PD; Gordon, DH; Kaminski, M; Major, P; Provencher, L; Rosen, LS; Seaman, J; Simeone, J	1
Castel, LD; Glendenning, GA; Li, Y; Schulman, KA; Timbie, JW; Weinfurt, KP	1
Carter, GD; Goss, AN	1
Cheng, YY; Huang, L; Kumta, SM; Lee, KM; Xu, JK; Zheng, MH	1
Chern, B; Copeman, M; De Abreu Lourenco, R; Joseph, D; Joshua, D; Lowe, S; Lynch, K; Pittman, K; Richardson, G; Schou, M	1
Bartsch, R; Hussian, D; Locker, GJ; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC	1
Aglietta, M; Cirillo, S; Gatti, M; Martincich, L; Montemurro, F; Regge, D; Russo, F	1
Berenson, J; Hirschberg, R	1
Forsea, AM; Geilen, CC; Müller, C; Orfanos, CE; Riebeling, C	1
Abbruzzese, A; Budillon, A; Caraglia, M; Colao, A; D'Alessandro, AM; Giuberti, G; Marra, M; Prete, SD; Tagliaferri, P; Tassone, P; Venuta, S; Viscomi, C; Vitale, G	1
Blaine, TA; Chang, SS; Doppelt, JD; Jung, KM; Kim, TW; Lee, FY; Suratwala, SJ; Winchester, RJ; Zhang, HZ	1
Greenberg, MS	1
Coleman, R; Conte, P	1
Boos, J; Lanvers-Kaminsky, C; Vorotnjak, M	1
Tanvetyanon, T	1
Coleman, RE; Glendenning, GA; Radeva, JI; Reed, SD; Schulman, KA	1
Harvey, HA	1
Khuri, F; Saba, N	1
Chou, T	1
Gralow, J	1
Balla, J	1
Lugassy, G	1
Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP	2
Cortizo, AM; McCarthy, AD; Vaisman, DN	1
Guarino, MJ; Hill, CE; Patel, K	1
Clegg, JP; Davie, AM; Guest, JF; McCloskey, E	1
Bagan, JV; Jimenez-Soriano, Y	1
Crowley, J; Durie, BG; Katz, M	1
Gordon, DH	1
Hande, K; Richardson, PG; Woo, SB	1
Dunleavy, R; Liauw, W; Lih, A; Links, M; Segelov, E; Ward, R	1
Cox, M; Makani, S; Mander, C; Wragg, K	1
Bourgeois, SL; Goodell, GG; Sarathy, AP	1
Corradi, D; Manfredi, M; Meleti, M; Merigo, E; Vescovi, P	1
Broumand, V; Fortin, M; Marx, RE; Sawatari, Y	1
Cull, G; Henley, D; Kaye, J; Walsh, J	1
Anagnostopoulos, A; Bamia, C; Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Koutsoukou, V; Melakopoulos, I; Moulopoulos, LA; Papadimitriou, C; Terpos, E	1
Abi Najm, S; Carrel, JP; Lesclous, P; Lombardi, T; Lysitsa, S; Samson, J	1
Cai, W; Gao, YJ; Li, PW; Liu, B; Mao, GG; Wang, SJ; Zhang, G; Zhang, Y; Zhou, YF	1
Vastag, B	1
Etayo-Pérez, A; Garatea-Crelgo, J; Martino-Gorbea, R; Pastor-Zuazaga, D; Sebastián-López, C	1
Eufinger, H; Hoefert, S	1
Robb-Nicholson, C	1
Abu-Id, MH; Açil, Y; Gottschalk, J; Kreusch, T	1
Stiff, PJ; Tanvetyanon, T	1
Bishop, PA; Hay, KD	1
Alexander, RE	1
Franke, HR; Verdijk, R; Vermes, I; Wolbers, F	1
Farrar, SK	1
Englund, K; Hatch, C; Hussein, MA; Isada, C; Karam, MA; Licata, A; Reed, J; Richmond, M; Smith, J; Thakkar, SG; Tomford, JW	1
Dimitrakopoulos, I; Karakasis, D; Magopoulos, C	1
Elting, LS; Migliorati, CA; Siegel, MA	1
Chen, NL; Diaz-Borjon, A; Lim, SS; Seyler, TM	1
Bemardeschi, P; Dentico, P; Fiorentini, G; Giustarini, G; Rossi, S; Turano, E	1
Gregersen, H; Neumann, B	1
Maisi, P; Raulo, SM; Sorsa, T	1
Weeda, LW	1
Bergsagel, PL; Carr, AB; Dalton, RJ; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Gollbach, KL; Greipp, PR; Hayman, SR; Kademani, D; Keller, EE; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Stewart, AK; Viozzi, CF; Witzig, TE; Zeldenrust, SR	1
Kademani, D; Koka, S; Lacy, MQ; Rajkumar, SV	1
Barrick, M	1
Baumann, A; Czerny, C; Eisenmenger, G; Ewers, R; Hoffmann, M; Moser, D; Pietschmann, P; Wutzl, A	1
Clemons, MJ; Cole, DE; Dranitsaris, G; Ooi, WS; Pritchard, KI; Sukovic, T; Trudeau, M; Verma, S; Wong, BY; Yogendran, G	1
Badros, A; Benderson, D; Karakunnel, J; Kathuria, S	1
Anderson, C; Birchall, L; Harrington, K; Meyer, B; Pandha, H; Relph, K; Wilson, N	1
McKenna, KE; Morris, TC; Ramadan, KM	1
Barnett, JB; de Lemos, ML; Hu, F; Levin, A; Moravan, V; O'Reilly, SE; Taylor, SC	1
Bandeira, F; Colares, V; Griz, L	1
Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E	1
Agurto P, J; Anguita C, T; Laissle C, G; Roa E, I	1
Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E	1
Dannemann, C; Grätz, KW; Riener, MO; Zwahlen, RA	1
Adamus, AT; Sherer, JT	1
Blasick, TM; Brown, RE; Quiery, AT; Zhang, PL	1
Armamento-Villareal, R; Civitelli, R; Napoli, N	1
Anaissie, EJ; Boyette, J; Clarke, BM; Stack, BC; Suen, JY; Vural, E	1
Baldini, E; Berto, P; Cortesi, E; Dauria, G; Roila, F; Schivazappa, C	1
Corso, A; Klersy, C; Lazzarino, M; Mangiacavalli, S; Pica, G; Varettoni, M; Zappasodi, P	1
Felicetti, L; Gissi, DB; Marchetti, C; Montebugnoli, L; Pelliccioni, GA; Pizzigallo, A	1
Bodmer, M; Kummer, O; Ramazzina, C; Rätz Bravo, AE; Zysset Aschmann, Y	1
Jawad, AS; Shenker, NG	1
Barrett-Lee, P; Bloomfield, D; Dougherty, L; Harries, M; Laing, R; Patel, H; Walker, M	1
Avanzati, A; De Paola, V; Gennari, L; Martini, G; Merlotti, D; Nuti, R; Valleggi, F	1
Bellomi, M; Bruschini, R; Cossu Rocca, M; Goldhirsch, A; Nole, F; Preda, L; Sanna, G; Verri, E	1
Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR	1
Engroff, SL; Kim, DD	1
Bonneterre, J; Cortet, B; Facon, T; Maes, JM; Magro, L; Penel, G; Vieillard, MH	1
Kohno, N; Yamada, K	1
Mukherjee, S; Oldfield, E; Song, Y	1
Brown, JJ; Ramalingam, L; Zacharin, MR	1
Abelson, A	1
Abu-Id, MH; Acil, Y; Gottschalk, J; Kreusch, T; Russo, PA; Springer, I; Warnke, PH; Wiltfang, J	1
Bedogni, A; Bedogni, G; Blandamura, S; Chiarini, L; Ferrari, F; Ferretti, M; Ferronato, G; Lo Muzio, L; Lo Russo, L; Lokmic, Z; Ninfo, V; Nocini, PF; Palumbo, C; Pietrogrande, F; Procopio, O; Ragazzo, M; Saia, G; Tregnaghi, A	1
McKeage, K; Plosker, GL	1
Bauss, F; Haiker, M; Künkele, KP; Lühe, A; Pfister, T; Schad, K; Suter, L; Zihlmann, C	1
Bigni, R; Castro, ED; Maia, RC; Silva, KL; Vasconcellos, DV; Vasconcelos, FC	1
Dodson, TB; Wessel, JH; Zavras, AI	1
Altundag, K; Bulut, N; Sari, E	1
Baldini, E; Barni, S; Berto, P; Cortesi, E; Dauria, G; Schivazappa, C	1
Gueiros, LA; Leão, JC; Lopes, MA	1
Fujii, Y; Fukui, I; Kijima, T; Okubo, Y; Suyama, T; Yonese, J	1
Duan, Z; Fang, S; Giordano, SH; Goodwin, JS; Hortobagyi, GN; Kuo, YF	1
Bareggi, C; Bianchi, C; Borgonovo, K; Cobelli, S; Farina, G; Garassino, M; La Verde, N; Mantica, C; Mihali, D; Pedretti, D; Perrone, S; Rizzo, A; Sburlati, P	1
Markowitz, GS; Perazella, MA	1
Bohle, GC; Carlson, DL; Estilo, CL; Farooki, A; Fornier, M; Halpern, JL; Huryn, JM; Lwin, PT; Riedel, ER; Schoder, H; Tunick, SJ; Van Poznak, CH; Wiliams, T; Zhou, Q	1
Chen, Q; Dong, M; Feng, FY; Feng, JF; Jiao, SC; Li, J; Liu, JW; Ren, J; Song, ST; Wang, XW; Wang, YJ; Wang, ZH; Xie, GR; Xu, N; Zhang, Y; Zhou, QH	1
Kalogeropoulou, C; Kardamakis, D; Vassiliou, V	1
Arnol, V; Cortizo, AM; Felice, JI; Gangoiti, MV; McCarthy, AD	1
Arnett, TR; Colston, KW; Key, ML; Orriss, IR	1
Bennett, CL; Boyd, I; Carson, K; Dimopoulos, M; Edwards, BJ; Farrugia, M; Gounder, M; Marx, R; McKoy, JM; Mehta, J; Migliorati, C; Obadina, E; Raisch, DW; Ruggiero, S; Singhal, S; Trifilio, S; West, D	1
Abildgaard, N; Gregersen, H; Lund, T; Marker, P; Vangsted, A	1
Bao, C; Gao, Y; Hu, J; Liu, X; Zou, S	1
Yamashita, S	2
Elad, S; Hardan, I; Lazarovici, TS; Taicher, S; Yahalom, R; Yarom, N	1
Brown, JJ; Zacharin, MR	1
Balasanian, E; Stanton, DC	1
Kawashima, H; Kuratsukuri, K; Matsumura, K; Matsuyama, M; Nakatani, T; Ohnishi, K; Tanaka, T; Yoshimura, R	1
Oliver, RJ; Seehra, J; Sloan, P	1
Fenner, M; Hinkmann, FM; Lell, MM; Neukam, FW; Nkenke, E; Stockmann, P; Vairaktaris, E	1
Baer, D; Han, MM; Hui, RL; Khoury, S; Liao, W; Liberty, D; Lo, JC; Martin, D; O'Ryan, FS	1
Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A	1
Cruz, LS; Fonseca, M; Machado, M; Tannus, G	1
Linneman, T; McMahan, J	1
De Paola, V; Gennari, L; Martini, G; Merlotti, D; Mossetti, G; Nuti, R; Rendina, D	1
Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K	1
Crawford, BS; Kraut, EH; McNulty, RM; Turowski, RC	1
Al-Nawas, B; Brüllmann, D; Gauss, L; Kämmerer, P; Klein, MO; Pabst, A; Walter, C; Ziebart, T	1
Cankaya, M; Ersoz, S; Gunhan, O; Kadioglu Duman, M; Muci, E; Pampu, AA; Senel, FC	1
Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M	1
Henry, C; Jahnke, W	1
Friedland, B; Treister, NS; Woo, SB	1
Berenson, J; Coleman, RE; Cook, RJ; Lipton, A; Terpos, E	1
de Jong, E; Hamdy, NA; Kuijpers, SC; van Merkesteyn, JP	1
Arduino, PG; Broccoletti, R; Dalmasso, P; Mozzati, M; Scoletta, M	1
Lindor, KD; Petz, JL; Silveira, MG; Treeprasertsuk, S	1
Byard, S; Duer, MJ; Ironside, MS; Reid, DG	1
Beninati, F; Ficarra, G	1
Arnold, RM; Weinstein, E	1
Chan, J; Hui, RL; Schottinger, JE; Spence, MM	1
Al-Nawas, B; Klein, M; Pabst, A; Walter, C; Ziebart, T	1
Deuber, HJ; Theiss, F	1
Jahanzeb, M; Mahtani, R	1
Aapro, M; Costa, L; Saad, F	1
Chiplunkar, SV; Dhar, S	1
Rajkumar, SV	1
Al-Nawas, B; Koch, FP; Pabst, AM; Taylor, KY; Walter, C; Ziebart, T	1
Henneman, L; Kulik, W; van Cruchten, AG; Waterham, HR	1
Barlow, WE; Biermann, JS; Bosserman, LD; Geoghegan, C; Hillner, BE; Janjan, NA; Temin, S; Theriault, RL; Van Poznak, CH; Von Roenn, JH; Yee, GC; Zuckerman, DS	1
Berenson, J; Dimopoulos, MA; Terpos, E	1
Taguchi, T	1
Amann, K; Hyckel, P; Neukam, F; Nkenke, E; Ries, J; Schlegel, K; Stockmann, P; Wehrhan, F	1
Burkley, B; Casanova, O; Ferreira, P; Gong, Y; Hou, W; Katz, J; Langaee, TY; Moreb, JS; Salmasinia, D	1
Barbieri, A; Buchpiguel, C; Cruz Júnior, AF; Guarniero, R	1
Pozzi, S; Raje, N	1
Ludwig, H; Zojer, N	1
Alloh Amichia, YC; Giumelli, B; Le Bars, P; Soueidan, A	1
Barbounis, V; Boziari, P; Karayianni, A; Kyrtsonis, MC; Migliorati, CA; Nicolatou-Galitis, O; Papadopoulou, E; Repousis, P; Sarri, T	1
Gander, H; Gruenbacher, G; Nussbaumer, O; Thurnher, M	1
Legrand, SB	1
Frustino, JL; Kossoff, EB; Ngamphaiboon, N; O'Connor, TL; Sullivan, MA	1
Forster, C; Glogauer, M; Kuiper, JW; Peel, S; Sun, C	1
Cannon, MJ; Goyne, H; Stone, PJ	1
Cozin, M; Cremers, S; Dadaian, SC; Landesberg, R; Pinker, BM; Raghavan, S; Solemani, K; Zuniga, JM	1
Bartl, R	1
Marchetti, C; Montebugnoli, L; Moretti, F; Pelliccioni, GA	1
Açil, Y; Gassling, V; Möller, B; Niehoff, P; Rachko, K; Simon, MJ; Wiltfang, J	1
Bissinger, O; Ehrenfeld, M; Kolk, A; Mast, G; Mücke, T; Otto, S; Pautke, C; Schreyer, C; Stürzenbaum, SR; Wolff, KD	1
Hayashi, N; Hortobagyi, GN; Liu, J; Niikura, N; Palla, SL; Theriault, RL; Tokuda, Y; Ueno, NT	1
Carson, DA; Cho, JS; Corr, M; Crain, B; Hayashi, T; Miller, LS; Norton, JT	1
Grätz, KW; Jacobsen, C; Metzler, P; Obwegeser, J; Rössle, M; Zemann, W	1
Della Rocca, J; Huxford-Phillips, RC; Kramer, SA; Lin, W; Liu, D; Wang, S	1
Basi, DL; Dudek, AZ; Gopalakrishnan, R; Huckabay, S; Hughes, PJ; Leach, JW; Lunos, S; Swenson, KK; Thumbigere-Math, V; Tu, L	1
Clark, OA; Djulbegovic, B; Glasmacher, A; Kumar, A; Mhaskar, R; Miladinovic, B; Redzepovic, J; Wheatley, K	1
Burke, N; Goeree, R; Hopkins, R; Tarride, JE; Xie, F	1
Bruscino-Raiola, F; Hewson, I; Syme, D	1
Freiberger, JJ; Kraft, KH; McGraw, T; Moon, RE; Padilla-Burgos, R; Piantadosi, CA; Stolp, BW; Suliman, HB	1
Hirschberg, R	1
Barros, ER; de Oliveira, TP; Lazaretti-Castro, M; Saraiva, GL	1
Brown, JE; Coleman, RE; Cook, RJ; Lipton, A	1
Bohle, G; Chou, JF; Estilo, CL; Halpern, J; Hansen, HJ; Huryn, JM; Riedel, E; Tunick, S; Watters, AL; Williams, T	1
Morgans, AK; Smith, MR	1
Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB	1
Edwards, S; Laing, K; McCarthy, J; McCrate, F; Murphy, L; Powell, E; Seal, M	1
Cavo, M; Dimopoulos, MA; Drake, MT; Durie, BG; García-Sanz, R; Jurczyszyn, A; Leleu, X; Lentzsch, S; Merlini, G; Morgan, G; Munshi, N; Raje, N; Rajkumar, SV; Reiman, T; Roodman, GD; Sezer, O; Shimizu, K; Spencer, A; Terpos, E; Turesson, I	1
Achel, DG; Alcaraz, M; Alcaraz-Saura, M; Olivares, A	1
Soydan, SS; Uckan, S	1
Afsie, S; Al-Nammari, SS; Timothy, T	1
Catalfamo, L; Centofanti, A; Cutroneo, G; De Ponte, FS; Favaloro, A; Runci, M; Siniscalchi, EN	1
Amoretti, N; Cornelis, F; Fournier, C; Gille, O; Hauger, O; Pillet, O; Truchetet, ME; Verdier, D	1
Hahn, NM; Kirkpatrick, K; Sharma, J; Sweeney, CJ; Yiannoutsos, CT	1
Brown, J; Fullarton, JR; Palmieri, C	1
Elahian, F; Lage, H; Mansouri, M; Mirzaei, SA; Mousavi, SS	1
Alegre, A; Bailén, A; Giraldo, P; Gironella, M	1
Balakumaran, A; Chung, K; Dodge, T; Edelsberg, J; Glass, AG; Lamerato, L; Lopez, A; Oster, G; Richert-Boe, KE; Richhariya, A; Wolff, GG	1
Bouxsein, ML; Brooks, DJ; Demay, MB; Louis, L; Zhu, ED	1
Chikazu, D; Hamada, H; Koizumi, T; Matsuo, A; Satomi, T	1
Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R	1
Hagelauer, N; Pabst, AM; Ulbrich, H; Walter, C; Ziebart, T	1
Bohgaki, M; Goto, M; Imoto, S; Matsumoto, E; Saigo, K	1
Angelis, CD; Burke, N; Giotis, A; Goeree, R; Habib, M; Hopkins, RB; Pasetka, M; Xie, F	1
Carson, K; Colditz, G; Gage, B; Luo, S; Sanfilippo, KM; Tomasson, M; Vij, R; Weilbaecher, K	1
Anderson, KC; Ghobrial, IM; Laubach, JP; Munshi, NC; Nemani, N; Patel, CG; Raje, NS; Richardson, PG; Santo, L; Schlossman, RL; Scullen, TA; Yee, AJ	1
Felsenberg, D; Gabbert, TI; Hoffmeister, B	1
Gamie, Z; Kenanidis, E; Kostakos, T; Kyrkos, J; Papamerkouriou, YM; Papavasiliou, K; Potoupnis, M; Sarris, I; Tsiridis, E	1
Cantrill, LC; Little, DG; Mikulec, K; Murphy, CM; Peacock, L; Schindeler, A	1
Criscitiello, C; Curigliano, G; De Laurentiis, M; De Placido, S; Esposito, A; Gelao, L; Goldhirsch, A; Santangelo, M; Viale, G	1
Arponen, H; Haukka, J; Mäkitie, O; Valta, H; Vuorimies, I; Waltimo-Sirén, J	1
Biggin, A; Briody, JN; Coorey, CP; Munns, CF; Zheng, L	1
Curtis, D; Lu, Y; Qiao, D; Wang, Z; Wen, X; Yao, Y; Zhao, H	1
Jacobs, C; Krüger, M; Pabst, AM; Sagheb, K; Walter, C; Ziebart, T	1
Bartoszewicz, M; Gluza, K; Junka, A; Kos, M; Smutnicka, D; Szymczyk, P	1
Fassier, F; Glorieux, FH; Montpetit, K; Ouellet, J; Palomo, T; Rauch, F; Sato, A	1
Ananth, CV; Burke, WM; Chen, L; Hershman, DL; Hou, JY; Neugut, AI; Richards, CA; Tergas, AI; Wright, JD	1
Glotzbecker, B; Mawardi, H; Richardson, P; Woo, SB	1
Du, S; Yang, L	1
Cunneen, TS; Goold, LA; Leibovitch, I; Martin, P; Pirbhai, A; Rajak, SN; Selva, D; Wilcsek, G	1
Balbontín-Ayala, F; Cañigral, A; Carlos, Fd; Cobo, T; Fernández-González, FJ; Fernández-Vázquez, JP; Gonzalo-Orden, JM; Sánchez-Lasheras, F; Vega, JA	1
Cai, XH; Feng, CJ; Huang, CY; Liu, XK; Lu, Y; Wang, L; Wang, Y; Wang, YS; Xu, Y; Yao, WX; Yu, P; Zhou, J; Zhu, WJ	1
Bouganim, N; Cella, D; Clemons, M; Dent, S; Dranitsaris, G; Gertler, S; Jacobs, C; Kuchuk, I; Mazzarello, S; Simos, S; Smith, S; Song, X; Vandermeer, L; Verma, S	1
Fujimoto, M; Fujiwara, Y; Hashimoto, J; Hirakawa, A; Kinoshita, F; Kodaira, M; Shimizu, C; Takahashi, N; Tamura, K; Tanaka, R; Yamamoto, H; Yonemori, K; Yunokawa, M	1
Mészaros, Á; Veszelyné Kotán, E	2
Egashira, K; Kawai, T; Kim, JY; Kiyama, T; Mawardi, H; Movila, A; Nishimura, K; Sasaki, H; Villa, A; Woo, SB	1
Biggin, A; Munns, CF	1
Ermer, MA; Kottmann, SC; Otten, JE; Pelz, K; Poxleitner, P; Wittmer, A	1
Crabtree, N; Högler, W; Sahota, J; Sakka, S; Saraff, V; Shaw, NJ	1
Moy, B; Somerfield, MR; Van Poznak, C	1
Barlow, WE; Biermann, JS; Bosserman, LD; Clemons, MJ; Dhesy-Thind, SK; Dillmon, MS; Eisen, A; Frank, ES; Jagsi, R; Jimenez, R; Moy, B; Somerfield, MR; Theriault, RL; Van Poznak, C; Vandenberg, TA; Yee, GC	1
Bahi-Buisson, N; Brailly-Tabard, S; Célestin, E; Charles, P; Durand, E; Fontaine, I; Lambert, AS; Linglart, A; Miladi, L; Rothenbuhler, A; Trabado, S; Wicart, P	1
Djulbegovic, B; Kumar, A; Mhaskar, R; Miladinovic, B	1
Filella, X; Florez, H; Guañabens, N; Mandelikova, S; Monegal, A; Peris, P	1
Alikasifoglu, A; Buyukyilmaz, G; Gonc, EN; Kandemir, N; Ozon, A; Simsek, OP	1
Estilo, CL; Huryn, JM; Liang, STY; Owosho, AA; Sax, AZ; Wu, K; Yom, SK	1
Kahn, JG; Matuoka, JY; Secoli, SR	1
Accordino, MK; Bhutani, D; Chen, Y; Hershman, DL; Hillyer, GC; Leng, S; Lentzsch, S; Lim, E; Neugut, AI; Tsai, WY; Wright, JD	1
Boston, S; Hoddinott, K; Mutsaers, AJ; Oblak, ML; Wood, GA	2
Chowdhury, A; Karamched, SR; Nosoudi, N; Parasaram, V; Parrish, J; Siclari, S	1
Kajima, M; Makita, C; Manabe, Y; Matsuo, M; Matsuyama, K; Tanaka, H	1
Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM	1
Arnaud, L; Javier, RM; Lebrun-Vignes, B; Pijnenburg, L; Salem, JE; Sibilia, J	1
de Roij van Zuijdewijn, C; Florquin, S; Roelofs, J; van Dorp, W; Verburgh, K	1
Hu, MI; Jara, MA; Varghese, J	1
Chworos, A; Gostynski, B; Madaj, R; Pawlowska, R	1
Bedogni, A; Campisi, G; Fusco, V	1
Au, PC; Baek, YH; Cheung, CL; Chung, WP; Kim, JH; Kleinman, NJ; Lai, EC; Lam, TC; Liao, TC; Lin, TC; Shen, CY; Shin, JY; Sing, CW; Wong, ICK	1
Berns, JS; Geara, AS; Shulman, R	1
Neal, TW; Schlieve, T	1
Aoki, K; Nakamura, M; Saito, N; Ueda, K; Yamamoto, Y; Yudasaka, M; Zhang, M	1
Shane, E; Walker, MD	1
Chang, AB; Conwell, LS; Jeffery, TC	1

Reviews

75 review(s) available for pamidronate and zoledronic acid

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Bisphosphonates, Old Friends of Bones and New Trends in Clinics. Journal of medicinal chemistry, 2021, 02-11, Volume: 64, Issue:3 Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compounding; Drug Delivery Systems; Humans	2021
Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer, 2000, Jan-01, Volume: 88, Issue:1 Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid	2000
Current and future directions in medical therapy: hypercalcemia. Cancer, 2000, Jun-15, Volume: 88, Issue:12 Suppl Topics: Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid	2000
Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jan-15, Volume: 19, Issue:2 Topics: Adult; Aged; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Neoplasms; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid	2001
[Tumor-induced hypercalcemia. Review of bisphosphonate treatment]. La Revue de medecine interne, 2001, Volume: 22, Issue:7 Topics: Diagnosis, Differential; Diagnostic Errors; Diphosphonates; Etidronic Acid; Fluid Therapy; Hematologic Neoplasms; Humans; Hypercalcemia; Imidazoles; Neoplasms; Pamidronate; Prognosis; Recurrence; Sodium Chloride; Treatment Outcome; Zoledronic Acid	2001
Multiple myeloma: present and future. Current opinion in oncology, 2002, Volume: 14, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Oxides; Pamidronate; Thalidomide; Zoledronic Acid	2002
[Bisphosphonates in the treatment of breast carcinoma]. Polskie Archiwum Medycyny Wewnetrznej, 2001, Volume: 106, Issue:2 Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Pamidronate; Zoledronic Acid	2001
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer investigation, 2002, Volume: 20 Suppl 2 Topics: Adenocarcinoma; Biomarkers; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteolysis; Osteoporosis; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Safety; Zoledronic Acid	2002
The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. The oncologist, 2002, Volume: 7, Issue:6 Topics: Anti-Inflammatory Agents; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Humans; Hypercalcemia; Imidazoles; Neoplasms; Pamidronate; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid	2002
Advances in the biology and treatment of myeloma bone disease. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 17 Topics: Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Clinical Trials as Topic; Cytokines; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Imidazoles; Immunoglobulin Fc Fragments; Intercellular Signaling Peptides and Proteins; Lymphokines; Membrane Glycoproteins; Multiple Myeloma; Osteoprotegerin; Pamidronate; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Zoledronic Acid	2002
Bisphosphonates and metastatic breast carcinoma. Cancer, 2003, Feb-01, Volume: 97, Issue:3 Suppl Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Forecasting; Glycoproteins; Humans; Imidazoles; Infusions, Intravenous; Osteoprotegerin; Pamidronate; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Zoledronic Acid	2003
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. American journal of clinical oncology, 2002, Volume: 25, Issue:6 Suppl 1 Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Data Interpretation, Statistical; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Male; Models, Statistical; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid	2002
Treatment of hypercalcemia of malignancy with bisphosphonates. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 21 Topics: Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid	2002
Injectable bisphosphonates in the treatment of postmenopausal osteoporosis. Aging clinical and experimental research, 2003, Volume: 15, Issue:4 Topics: Anti-Inflammatory Agents; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Zoledronic Acid	2003
Bisphosphonate therapy in the oncology setting. Expert opinion on emerging drugs, 2003, Volume: 8, Issue:2 Topics: Administration, Oral; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Pamidronate; Zoledronic Acid	2003
Hypercalcemia of malignancy. Seminars in nephrology, 2004, Volume: 24, Issue:1 Topics: Antineoplastic Agents; Diphosphonates; Forecasting; Humans; Hypercalcemia; Imidazoles; Neoplasms; Pamidronate; Parathyroid Hormone-Related Protein; Zoledronic Acid	2004
Safety and convenience of a 15-minute infusion of zoledronic acid. The oncologist, 2004, Volume: 9, Issue:3 Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid	2004
Bisphosphonates in the treatment of skeletal metastases. Seminars in oncology, 2004, Volume: 31, Issue:5 Suppl 10 Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Imidazoles; Pamidronate; Zoledronic Acid	2004
Management of bone metastases in breast cancer. Current treatment options in oncology, 2005, Volume: 6, Issue:2 Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Middle Aged; Palliative Care; Pamidronate; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid	2005
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy. Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 12 Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Pamidronate; Postmenopause; Triazoles; Zoledronic Acid	2004
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications. Oncology, 2005, Volume: 68, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clodronic Acid; Diphosphonates; Etidronic Acid; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Ibandronic Acid; Imidazoles; Lung Neoplasms; Pamidronate; Positron-Emission Tomography; Predictive Value of Tests; Therapeutic Equivalency; Zoledronic Acid	2005
[Multiple myeloma--recent advances in diagnosis and treatment]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Multiple Myeloma; Neoplasm Staging; Pamidronate; Protease Inhibitors; Pyrazines; Thalidomide; Zoledronic Acid	2005
Bisphosphonates in breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:5 Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Neoplasm Staging; Pamidronate; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid	2005
Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer. Clinical breast cancer, 2005, Volume: 5 Suppl, Issue:2 Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Osteonecrosis; Pamidronate; Quality of Life; Randomized Controlled Trials as Topic; United States; Women's Health; Zoledronic Acid	2005
New therapeutic agents for the treatment of bone diseases. Expert opinion on biological therapy, 2005, Volume: 5, Issue:6 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid	2005
Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. Clinical breast cancer, 2005, Volume: 6, Issue:2 Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid	2005
[Bisphosphonate-associated osteonecrosis of the jaw]. Mund-, Kiefer- und Gesichtschirurgie : MKG, 2006, Volume: 10, Issue:2 Topics: Aged; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Mandible; Maxilla; Middle Aged; Neoplasms; Osteoporosis; Pamidronate; Risk Factors; Zoledronic Acid	2006
Management of the adverse effects associated with intravenous bisphosphonates. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:6 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Inflammation; Infusions, Intravenous; Osteoclasts; Pamidronate; Zoledronic Acid	2006
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. The Lancet. Oncology, 2006, Volume: 7, Issue:6 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Dental Care for Chronically Ill; Diphosphonates; Humans; Imidazoles; Jaw; Mandibular Diseases; Multiple Myeloma; Osteonecrosis; Pamidronate; Practice Guidelines as Topic; Time Factors; Zoledronic Acid	2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clinic proceedings, 2006, Volume: 81, Issue:8 Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Minnesota; Multiple Myeloma; Osteoporosis; Pamidronate; Practice Guidelines as Topic; Zoledronic Acid	2006
Scleritis complicating zoledronic acid infusion. Clinical lymphoma & myeloma, 2006, Volume: 7, Issue:2 Topics: Aged; Anti-Inflammatory Agents; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Multiple Myeloma; Pamidronate; Radiography; Scleritis; Zoledronic Acid	2006
[Treatment of Paget's disease of bone: importance of the zoledronic acid]. Arquivos brasileiros de endocrinologia e metabologia, 2006, Volume: 50, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Diphosphonates; Female; Follow-Up Studies; Genetic Predisposition to Disease; Humans; Hypercalcemia; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteitis Deformans; Pamidronate; Remission Induction; Treatment Outcome; Zoledronic Acid	2006
[Zoledronate-associated end stage renal failure and hypocalcaemia]. Praxis, 2007, Apr-25, Volume: 96, Issue:17 Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Biopsy; Bone Density Conservation Agents; Calcium; Creatinine; Diphosphonates; Disease Progression; Female; Follow-Up Studies; Humans; Hypocalcemia; Imidazoles; Kidney Failure, Chronic; Kidney Tubules; Middle Aged; Multiple Myeloma; Pamidronate; Renal Dialysis; Risk Factors; Switzerland; Time Factors; Vitamin D; Zoledronic Acid	2007
[Clinical study of bisphosphonates for bone metastasis in breast cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Osteoclasts; Pain; Pamidronate; Quality of Life; Randomized Controlled Trials as Topic; Zoledronic Acid	2007
A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg. Current medical research and opinion, 2008, Volume: 24, Issue:3 Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Etidronic Acid; Humans; Imidazoles; Middle Aged; Osteitis Deformans; Pamidronate; Risedronic Acid; Risk Factors; Treatment Outcome; Zoledronic Acid	2008
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. PharmacoEconomics, 2008, Volume: 26, Issue:3 Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Quality-Adjusted Life Years; Zoledronic Acid	2008
Bisphosphonate nephrotoxicity. Kidney international, 2008, Volume: 74, Issue:11 Topics: Diphosphonates; Glomerulosclerosis, Focal Segmental; Humans; Imidazoles; Kidney Cortex Necrosis; Kidney Diseases; Pamidronate; Practice Guidelines as Topic; Zoledronic Acid	2008
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. The Lancet. Oncology, 2008, Volume: 9, Issue:12 Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Drug Approval; Female; Humans; Imidazoles; Incidence; Infusions, Intravenous; Jaw; Male; Osteonecrosis; Pamidronate; Precipitating Factors; Tooth Extraction; United States; United States Food and Drug Administration; Zoledronic Acid	2008
[Bisphosphonates and other new therapeutic agents for the treatmednt of osteogenesis imperfecta]. Clinical calcium, 2009, Volume: 19, Issue:2 Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Child, Preschool; Clinical Trials as Topic; Denosumab; Diphosphonates; Drug Administration Schedule; Genetic Therapy; Humans; Imidazoles; Infusions, Intravenous; Osteogenesis Imperfecta; Pamidronate; RANK Ligand; Severity of Illness Index; Stem Cell Transplantation; Teriparatide; Zoledronic Acid	2009
Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials. Clinical therapeutics, 2009, Volume: 31, Issue:5 Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Male; Pamidronate; Randomized Controlled Trials as Topic; Risk; Survival Analysis; Treatment Outcome; Zoledronic Acid	2009
The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone. Mini reviews in medicinal chemistry, 2009, Volume: 9, Issue:9 Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Osteitis Deformans; Pamidronate; Zoledronic Acid	2009
[Bone and joint diseases in children. Bisphosphonates in osteogenesis imperfecta]. Clinical calcium, 2010, Volume: 20, Issue:6 Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Humans; Imidazoles; Infant; Infusions, Intravenous; Osteogenesis Imperfecta; Pamidronate; Severity of Illness Index; Zoledronic Acid	2010
Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects. Head and neck pathology, 2007, Volume: 1, Issue:2 Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Mandible; Osteonecrosis; Pamidronate; Retrospective Studies; Zoledronic Acid	2007
[Bisphosphonates in adjuvant therapy of breast cancer]. Medizinische Klinik (Munich, Germany : 1983), 2010, Volume: 105, Issue:9 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Controlled Clinical Trials as Topic; Diphosphonates; Drug Approval; Estrogen Antagonists; Evidence-Based Medicine; Female; Humans; Imidazoles; Neoplasm Staging; Osteoporosis; Pamidronate; Survival Rate; Zoledronic Acid	2010
Bisphosphonates as anticancer therapy for early breast cancer. Clinical breast cancer, 2010, Oct-01, Volume: 10, Issue:5 Topics: Apoptosis; Bone Density Conservation Agents; Breast Neoplasms; Cell Proliferation; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Neovascularization, Physiologic; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid	2010
Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. Critical reviews in oncology/hematology, 2011, Volume: 77 Suppl 1 Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Mice; Multiple Myeloma; Osteolysis; Pamidronate; Risk Factors; Spinal Cord Compression; Zoledronic Acid	2011
[Encounter of cancer cells with bone. Treatment of bone metastases from breast cancer]. Clinical calcium, 2011, Volume: 21, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Molecular Targeted Therapy; Osteoclasts; Pamidronate; RANK Ligand; Strontium; Zoledronic Acid	2011
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. The oncologist, 2011, Volume: 16, Issue:5 Topics: Acute-Phase Reaction; Bone Diseases; Diphosphonates; Endothelial Cells; Humans; Imidazoles; Multiple Myeloma; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronate; Practice Guidelines as Topic; Zoledronic Acid	2011
Supportive therapy in multiple myeloma. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183 Topics: Anemia; Blood Transfusion; Bone Diseases; Calcitonin; Clodronic Acid; Diphosphonates; Erythropoietin; Fractures, Bone; Hematinics; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteoporosis; Pamidronate; Recombinant Proteins; Renal Insufficiency; Zoledronic Acid	2011
Modern management of malignant hypercalcemia. The American journal of hospice & palliative care, 2011, Volume: 28, Issue:7 Topics: Bone Density Conservation Agents; Calcitonin; Clinical Protocols; Diphosphonates; Fluid Therapy; Gallium; Humans; Hypercalcemia; Imidazoles; Neoplasms; Palliative Care; Pamidronate; Parathyroid Hormone-Related Protein; Zoledronic Acid	2011
Antitumor effects of bisphosphonates: from the laboratory to the clinic. Current opinion in supportive and palliative care, 2011, Volume: 5, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Breast Neoplasms; Cell Adhesion Molecules; Diphosphonates; Female; Humans; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Zoledronic Acid	2011
Bisphosphonates in multiple myeloma: a network meta-analysis. The Cochrane database of systematic reviews, 2012, May-16, Issue:5 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid	2012
Renal complications from bisphosphonate treatment. Current opinion in supportive and palliative care, 2012, Volume: 6, Issue:3 Topics: Acute Kidney Injury; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Kidney; Kidney Diseases; Nephrotic Syndrome; Pamidronate; Risk Factors; Zoledronic Acid	2012
Bone-targeted agents: preventing skeletal complications in prostate cancer. The Urologic clinics of North America, 2012, Volume: 39, Issue:4 Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Osteoclasts; Osteoporosis; Pamidronate; Prostatic Neoplasms; Quality of Life; Samarium; Toremifene; Zoledronic Acid	2012
A Surgeon's guide to advances in the pharmacological management of acute Charcot neuroarthropathy. Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons, 2013, Volume: 19, Issue:4 Topics: Alendronate; Alkaline Phosphatase; Arthropathy, Neurogenic; Bone Density Conservation Agents; Calcitonin; Diphosphonates; Humans; Hydroxyproline; Imidazoles; Immobilization; Insulin-Like Growth Factor I; Pamidronate; Randomized Controlled Trials as Topic; RANK Ligand; Skin Temperature; Zoledronic Acid	2013
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Dec-15, Volume: 19, Issue:24 Topics: Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Neoplasm Metastasis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid	2013
Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review. European journal of haematology, 2014, Volume: 92, Issue:3 Topics: Antineoplastic Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Drug Monitoring; Humans; Ibandronic Acid; Imidazoles; Multiple Myeloma; Pamidronate; Zoledronic Acid	2014
Treatment of multiple myeloma bone disease: experimental and clinical data. Expert opinion on biological therapy, 2015, Volume: 15, Issue:2 Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Quality of Life; Zoledronic Acid	2015
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. Cancer treatment reviews, 2015, Volume: 41, Issue:2 Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bone Remodeling; Bone Resorption; Clodronic Acid; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Immune System; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Treatment Outcome; Zoledronic Acid	2015
Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis. The oncologist, 2015, Volume: 20, Issue:4 Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid	2015
Efficacy and Safety of Zoledronic Acid and Pamidronate Disodium in the Treatment of Malignant Skeletal Metastasis: A Meta-Analysis. Medicine, 2015, Volume: 94, Issue:42 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Pamidronate; Treatment Outcome; Zoledronic Acid	2015
Bisphosphonate-Induced Orbital Inflammation: A Case Series and Review. Orbit (Amsterdam, Netherlands), 2015, Volume: 34, Issue:6 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Orbital Cellulitis; Orbital Myositis; Pamidronate; Radiography; Retrospective Studies; Zoledronic Acid	2015
Experimental evidence of pharmacological management of anchorage in Orthodontics: A systematic review. Dental press journal of orthodontics, 2015, Volume: 20, Issue:5 Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents; Antioxidants; Bone Remodeling; Celecoxib; Clodronic Acid; Diclofenac; Diphosphonates; Humans; Imidazoles; Interferon-gamma; Isoxazoles; Lactones; Mice; Orthodontic Anchorage Procedures; Osteoclasts; Osteoprotegerin; Pamidronate; Rats; Resveratrol; Stilbenes; Sulfones; Tooth Mobility; Tooth Movement Techniques; Zoledronic Acid	2015
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I]. Acta pharmaceutica Hungarica, 2016, Volume: 86, Issue:1 Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid	2016
Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta. Current osteoporosis reports, 2017, Volume: 15, Issue:5 Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Orthopedic Procedures; Osteogenesis Imperfecta; Pamidronate; Physical Therapy Modalities; Quality of Life; Zoledronic Acid	2017
Bisphosphonates in multiple myeloma: an updated network meta-analysis. The Cochrane database of systematic reviews, 2017, 12-18, Volume: 12 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Disease-Free Survival; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid	2017
Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review. The European journal of health economics : HEPAC : health economics in prevention and care, 2019, Volume: 20, Issue:4 Topics: Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Health Care Costs; Humans; Pamidronate; Zoledronic Acid	2019
Bisphosphosphonate-calcium phosphate cement composite and its properties. Bio-medical materials and engineering, 2019, Volume: 30, Issue:3 Topics: Alendronate; Animals; Biocompatible Materials; Bone Density Conservation Agents; Calcium Phosphates; Diphosphonates; Drug Carriers; Drug Delivery Systems; Etidronic Acid; Humans; Pamidronate; Zoledronic Acid	2019
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Denosumab; Diphosphonates; Etidronic Acid; Humans; Male; Network Meta-Analysis; Pamidronate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Zoledronic Acid	2020
Atrial fibrillation in patients treated with intravenous zoledronic or pamidronic acid: a pharmacoepidemiological study. European journal of endocrinology, 2021, Volume: 184, Issue:3 Topics: Administration, Intravenous; Aged; Aged, 80 and over; Atrial Fibrillation; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Humans; Male; North America; Pamidronate; Pharmacoepidemiology; Pharmacovigilance; World Health Organization; Zoledronic Acid	2021
Bisphosphonate nephropathy: A case series and review of the literature. British journal of clinical pharmacology, 2021, Volume: 87, Issue:9 Topics: Animals; Diphosphonates; Humans; Imidazoles; Kidney Diseases; Pamidronate; Rats; Zoledronic Acid	2021
Adverse events associated with bone-directed therapies in patients with cancer. Bone, 2022, Volume: 158 Topics: Antibodies, Monoclonal; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Pamidronate; Zoledronic Acid	2022
Hypercalcemia: A Review. JAMA, 2022, 10-25, Volume: 328, Issue:16 Topics: Calcium; Coma; COVID-19; Dehydration; Denosumab; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Immune Checkpoint Inhibitors; Nausea; Neoplasms; Pamidronate; Parathyroid Hormone; SARS-CoV-2; Sleepiness; Sodium Chloride Symporter Inhibitors; Vitamin A; Vitamin D; Vomiting; Zoledronic Acid	2022
Bisphosphonates for osteoporosis in people with cystic fibrosis. The Cochrane database of systematic reviews, 2023, 01-10, Volume: 1 Topics: Adult; Alendronate; Bone Density Conservation Agents; Child; Cystic Fibrosis; Diphosphonates; Female; Fractures, Bone; Humans; Musculoskeletal Pain; Osteoporosis; Pamidronate; Quality of Life; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid	2023

Trials

26 trial(s) available for pamidronate and zoledronic acid

Article	Year
An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcified tissue international, 1997, Volume: 61, Issue:5 Topics: Acute-Phase Reaction; Adult; Bone Diseases; Carrier Proteins; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Interleukin-1; Interleukin-6; Leukocyte Count; Male; Middle Aged; Pamidronate; Tumor Necrosis Factor-alpha; Zoledronic Acid	1997
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer, 2001, Apr-01, Volume: 91, Issue:7 Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Collagen; Collagen Type I; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Pamidronate; Peptides; Zoledronic Acid	2001
Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jul-15, Volume: 19, Issue:14 Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Osteolysis; Pamidronate; Time Factors; Zoledronic Acid	2001
Bisphosphonates and metastatic breast carcinoma. Cancer, 2003, Feb-01, Volume: 97, Issue:3 Suppl Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Forecasting; Glycoproteins; Humans; Imidazoles; Infusions, Intravenous; Osteoprotegerin; Pamidronate; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Zoledronic Acid	2003
Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials. American journal of clinical oncology, 2002, Volume: 25, Issue:6 Suppl 1 Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid	2002
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 2003, Oct-15, Volume: 98, Issue:8 Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Pamidronate; Zoledronic Acid	2003
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer, 2004, Jan-01, Volume: 100, Issue:1 Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fractures, Bone; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteolysis; Pamidronate; Risk Factors; Spinal Cord Compression; Zoledronic Acid	2004
Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Medical care, 2004, Volume: 42, Issue:2 Topics: Bone Neoplasms; Breast Neoplasms; Canada; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Outcome and Process Assessment, Health Care; Pamidronate; Prospective Studies; Quality of Life; United States; Zoledronic Acid	2004
Bisphosphonate infusions: patient preference, safety and clinic use. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2004, Volume: 12, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Confidence Intervals; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Outpatients; Pamidronate; Patient Satisfaction; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome; Zoledronic Acid	2004
[Phase II randomized clinical trail of zoledronic acid in treating metastatic bone pain of malignancy]. Ai zheng = Aizheng = Chinese journal of cancer, 2005, Volume: 24, Issue:12 Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Male; Mannitol; Middle Aged; Pain, Intractable; Pamidronate; Prospective Studies; Zoledronic Acid	2005
Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eight patients previously treated with multiple myeloma. Journal of experimental & clinical cancer research : CR, 2003, Volume: 22, Issue:4 Suppl Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Sedimentation; Dexamethasone; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pamidronate; Prognosis; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome; Zoledronic Acid	2003
Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-20, Volume: 24, Issue:30 Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Disease Progression; Drug Resistance; Female; Humans; Imidazoles; Middle Aged; Pain; Palliative Care; Pamidronate; Prospective Studies; Treatment Outcome; Zoledronic Acid	2006
Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2007, Volume: 104, Issue:4 Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Analysis of Variance; Anti-Bacterial Agents; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Linear Models; Male; Metronidazole; Middle Aged; Osteonecrosis; Pamidronate; Prospective Studies; Zoledronic Acid	2007
Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2007, Volume: 22, Issue:10 Topics: Aged; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Male; Osteitis Deformans; Pain; Pamidronate; Quality of Life; Time Factors; Zoledronic Acid	2007
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. The oncologist, 2007, Volume: 12, Issue:9 Topics: Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Creatinine; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Injections, Intravenous; Male; Multiple Myeloma; Osteoclasts; Osteolysis; Pamidronate; Peptides; Retrospective Studies; Risk Assessment; Survival Rate; Treatment Outcome; Zoledronic Acid	2007
[Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:3 Topics: Adult; Aged; Analgesics; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Colorectal Neoplasms; Creatinine; Diphosphonates; Double-Blind Method; Female; Fever; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Pain, Intractable; Pamidronate; Peptides; Prospective Studies; Vomiting; Zoledronic Acid	2008
Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. Journal of pediatric endocrinology & metabolism : JPEM, 2009, Volume: 22, Issue:1 Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Child; Child Development; Child, Preschool; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Injections, Intravenous; Kidney; Liver; Male; Osteogenesis Imperfecta; Osteoporosis; Pamidronate; Treatment Outcome; Zoledronic Acid	2009
Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clinical oral investigations, 2010, Volume: 14, Issue:3 Topics: Aged; Bone Density Conservation Agents; Bone Marrow; Contrast Media; Diphosphonates; Female; Follow-Up Studies; Gadolinium; Humans; Imidazoles; Jaw Diseases; Magnetic Resonance Imaging; Male; Mandibular Diseases; Maxillary Diseases; Organometallic Compounds; Osteolysis; Osteonecrosis; Pamidronate; Radiography, Panoramic; Tomography, X-Ray Computed; Zoledronic Acid	2010
Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid. The Annals of pharmacotherapy, 2010, Volume: 44, Issue:9 Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Humans; Imidazoles; Male; Pamidronate; Prostatic Neoplasms; Retrospective Studies; Risk; Treatment Outcome; Zoledronic Acid	2010
A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosphonate-associated osteonecrosis of the jaws. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2011, Volume: 112, Issue:6 Topics: Aged; Aged, 80 and over; Alendronate; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Local; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Chlorhexidine; Diphosphonates; Drug Combinations; Female; Follow-Up Studies; Humans; Imidazoles; Male; Metronidazole; Middle Aged; Mouthwashes; Oral Hygiene; Pain Measurement; Pamidronate; Prospective Studies; Salicylates; Terpenes; Treatment Outcome; Zoledronic Acid	2011
What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2012, Volume: 70, Issue:7 Topics: Aged; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Combined Modality Therapy; Debridement; Diphosphonates; Female; Follow-Up Studies; Gingiva; Humans; Hyperbaric Oxygenation; Imidazoles; Male; Multiple Myeloma; Osteoporosis; Pain Management; Pamidronate; Prospective Studies; Quality of Life; Treatment Outcome; Wound Healing; Zoledronic Acid	2012
Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of pediatric endocrinology & metabolism : JPEM, 2012, Volume: 25, Issue:5-6 Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Infant; Male; Osteogenesis Imperfecta; Pamidronate; Prospective Studies; Treatment Outcome; Zoledronic Acid	2012
Bisphosphonate therapy for unresectable symptomatic benign bone tumors: a long-term prospective study of tolerance and efficacy. Bone, 2014, Volume: 58 Topics: Adolescent; Adult; Bone Density Conservation Agents; Bone Neoplasms; Child; Diphosphonates; Female; Humans; Imidazoles; Male; Pamidronate; Prospective Studies; Radiography; Time Factors; Treatment Outcome; Young Adult; Zoledronic Acid	2014
Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event. Clinical genitourinary cancer, 2014, Volume: 12, Issue:1 Topics: Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Remodeling; Denosumab; Diphosphonates; Disease Progression; Disease-Free Survival; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Osteocalcin; Pamidronate; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid	2014
The long-term effects of switching from active intravenous bisphosphonate treatment to low-dose maintenance therapy in children with osteogenesis imperfecta. Hormone research in paediatrics, 2015, Volume: 83, Issue:3 Topics: Administration, Intravenous; Bone Density; Child; Child, Preschool; Diphosphonates; Drug Substitution; Female; Humans; Imidazoles; Infant; Male; Osteogenesis Imperfecta; Pamidronate; Radiography; Spine; Zoledronic Acid	2015
A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer. Breast cancer research and treatment, 2016, Volume: 155, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Drug Substitution; Female; Humans; Imidazoles; Middle Aged; Palliative Care; Pamidronate; Quality of Life; Treatment Outcome; Zoledronic Acid	2016

Other Studies

224 other study(ies) available for pamidronate and zoledronic acid

Article	Year
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs. Journal of medicinal chemistry, 2002, Jul-04, Volume: 45, Issue:14 Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats	2002
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). Journal of medicinal chemistry, 2002, Aug-15, Volume: 45, Issue:17 Topics: Animals; Bone Resorption; Calcitriol; Diphosphonates; Hypercalcemia; Imidazoles; In Vitro Techniques; Kidney; Mice; Pamidronate; Parathyroidectomy; Rats; Skull; Structure-Activity Relationship; Thyroidectomy; Zoledronic Acid	2002
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. Journal of medicinal chemistry, 2004, Jan-01, Volume: 47, Issue:1 Topics: Animals; Antimalarials; Antiprotozoal Agents; Cell Line; Cricetinae; Diphosphonates; Entamoeba histolytica; Entamoebiasis; Humans; In Vitro Techniques; Liver Abscess; Malaria; Mice; Mice, Inbred BALB C; Plasmodium berghei; Plasmodium falciparum; Structure-Activity Relationship	2004
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption. Journal of medicinal chemistry, 2005, Apr-21, Volume: 48, Issue:8 Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bone Resorption; Calcium; Dictyostelium; Diphosphonates; Geranyltranstransferase; Humans; In Vitro Techniques; Leishmania major; Metatarsal Bones; Mice; Models, Molecular; Pyridinium Compounds; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; Trypanocidal Agents	2005
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations. Journal of medicinal chemistry, 2005, May-05, Volume: 48, Issue:9 Topics: Aldose-Ketose Isomerases; Alkyl and Aryl Transferases; Animals; Antiprotozoal Agents; Cell Line; Diphosphonates; Fosfomycin; Geranyltranstransferase; Humans; Mice; Models, Molecular; Multienzyme Complexes; Oxidoreductases; Quantitative Structure-Activity Relationship; Toxoplasma; Toxoplasmosis	2005
Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines. Journal of medicinal chemistry, 2006, Sep-21, Volume: 49, Issue:19 Topics: Antineoplastic Agents; Benzene Derivatives; Cell Line, Tumor; Diphosphonates; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Pyridines; Quinolines; Structure-Activity Relationship; Terphenyl Compounds	2006
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin. Journal of medicinal chemistry, 2006, Dec-14, Volume: 49, Issue:25 Topics: Anti-Bacterial Agents; Cluster Analysis; Diphosphonates; Drug Synergism; Escherichia coli K12; Fosfomycin; Gene Expression; Geranyltranstransferase; Models, Molecular; Oligonucleotide Array Sequence Analysis; Quantitative Structure-Activity Relationship; Terpenes	2006
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. Journal of medicinal chemistry, 2008, Apr-10, Volume: 51, Issue:7 Topics: Binding Sites; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Models, Molecular; Molecular Structure; Nitrogen; Stereoisomerism; Structure-Activity Relationship; Time Factors	2008
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. Journal of medicinal chemistry, 2008, Sep-25, Volume: 51, Issue:18 Topics: Antineoplastic Agents; Crystallography, X-Ray; Diphosphonates; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Farnesyltranstransferase; Humans; K562 Cells; Magnetic Resonance Spectroscopy; Models, Molecular; Quantitative Structure-Activity Relationship	2008
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6 Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics	2010
Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry. Journal of medicinal chemistry, 2011, Sep-08, Volume: 54, Issue:17 Topics: Amino Acid Motifs; Chemistry, Pharmaceutical; Humans; Organophosphonates; Phosphinic Acids	2011
Low toxicity and unprecedented anti-osteoclast activity of a simple sulfur-containing gem-bisphosphonate: a comparative study. European journal of medicinal chemistry, 2013, Volume: 65 Topics: Animals; Apoptosis; Cells, Cultured; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Mice; Molecular Structure; Molecular Weight; Osteoclasts; Structure-Activity Relationship; Sulfur	2013
Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility. Bioorganic & medicinal chemistry letters, 2020, 12-01, Volume: 30, Issue:23 Topics: Acetamides; Animals; Antimitotic Agents; Cell Line, Tumor; Diphosphonates; Drug Screening Assays, Antitumor; Embryo, Nonmammalian; Humans; Indoles; Sea Urchins; Solubility	2020
Effects of two novel bisphosphonates on bone cells in vitro. Bone and mineral, 1994, Volume: 26, Issue:2 Topics: Animals; Bone and Bones; Bone Resorption; Breast Neoplasms; Cell Count; Cells, Cultured; Culture Media, Conditioned; Diphosphonates; DNA; Dose-Response Relationship, Drug; Edetic Acid; Female; Humans; Imidazoles; Osteoblasts; Osteoclasts; Pamidronate; Rats; Tumor Cells, Cultured; Zoledronic Acid	1994
Pamidronate (Aredia) and zoledronate: update on clinical results. Introduction. British journal of clinical practice. Supplement, 1996, Volume: 87 Topics: Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Organophosphorus Compounds; Osteoblasts; Pamidronate; Zoledronic Acid	1996
Zoledronate: the preclinical pharmacology. British journal of clinical practice. Supplement, 1996, Volume: 87 Topics: Animals; Bone Resorption; Cholecalciferol; Depression, Chemical; Diphosphonates; Disease Models, Animal; Female; Hypercalcemia; Imidazoles; Ovariectomy; Pamidronate; Parathyroidectomy; Rats; Thyroidectomy; Zoledronic Acid	1996
Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. The Anatomical record, 1997, Volume: 249, Issue:4 Topics: Animals; Anti-Bacterial Agents; Biomarkers; Bone Development; Calcium; Demeclocycline; Diphosphonates; Dose-Response Relationship, Drug; Femur; Fluoresceins; Growth Plate; Hydroxyproline; Imidazoles; Indicators and Reagents; Injections, Subcutaneous; Male; Pamidronate; Rats; Rats, Sprague-Dawley; Tibia; Zoledronic Acid	1997
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia, 1998, Volume: 12, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Calcium; Cell Death; Cell Division; Cell Survival; Chelating Agents; Diphosphonates; Drug Screening Assays, Antitumor; Humans; Imidazoles; Interleukin-6; Multiple Myeloma; Pamidronate; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Zoledronic Acid	1998
Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1999, Volume: 14, Issue:12 Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Bone Resorption; Cell Division; Cell Survival; Diphosphonates; Humans; Imidazoles; Interleukin-1; Interleukin-6; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Multiple Myeloma; Pamidronate; Tumor Cells, Cultured; Zoledronic Acid	1999
Bisphosphonates induce apoptosis in human breast cancer cell lines. British journal of cancer, 2000, Volume: 82, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Division; Cell Nucleus; Cell Survival; Clodronic Acid; Diphosphonates; DNA Fragmentation; Female; Humans; Imidazoles; Kinetics; Pamidronate; Pyrrolidines; Tumor Cells, Cultured; Zoledronic Acid	2000
Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer research, 2000, Nov-01, Volume: 60, Issue:21 Topics: Alkaline Phosphatase; Anti-Inflammatory Agents; Antineoplastic Agents; Bone Development; Calcification, Physiologic; Cell Differentiation; Cell Division; Cells, Cultured; Chelating Agents; Collagen; Diphosphonates; Edetic Acid; Etidronic Acid; Fetus; Gene Expression; Humans; Imidazoles; Osteoblasts; Pamidronate; Proteins; Zoledronic Acid	2000
[Significant therapeutic progression in tumor-induced bone diseases. This year's Robert Koch Award is awarded to Novartis Oncology]. Medizinische Klinik (Munich, Germany : 1983), 2000, Oct-15, Volume: 95 Suppl 2 Topics: Antineoplastic Agents; Awards and Prizes; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Pamidronate; Zoledronic Acid	2000
Bisphosphonates induce breast cancer cell death in vitro. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2000, Volume: 15, Issue:11 Topics: Amino Acid Chloromethyl Ketones; Annexins; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase Inhibitors; Caspases; Cell Death; Cell Nucleus; Clodronic Acid; Cysteine Proteinase Inhibitors; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Ibandronic Acid; Imidazoles; Kinetics; Pamidronate; Tumor Cells, Cultured; Zoledronic Acid	2000
Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM). Breast cancer (Tokyo, Japan), 2000, Volume: 7, Issue:4 Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Osteoclasts; Osteoporosis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid	2000
Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer research, 2001, Mar-15, Volume: 61, Issue:6 Topics: Antineoplastic Agents; Cell Cycle; Cell Division; Cell Survival; Diphosphonates; Growth Inhibitors; Humans; Imidazoles; Male; Pamidronate; Prostatic Neoplasms; Tumor Cells, Cultured; Zoledronic Acid	2001
Bisphosphonates and nephrocalcinosis in a rabbit leg lengthening model: a histological and therapeutic comparison. Pharmacology & toxicology, 2001, Volume: 89, Issue:3 Topics: Animals; Bone Density; Bone Regeneration; Diphosphonates; Disease Models, Animal; Imidazoles; Kidney; Male; Nephrocalcinosis; Osteogenesis, Distraction; Pamidronate; Rabbits; Zoledronic Acid	2001
A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2001, Volume: 9, Issue:7 Topics: Antineoplastic Agents; Bone Neoplasms; Costs and Cost Analysis; Diphosphonates; Economics, Pharmaceutical; Humans; Imidazoles; Palliative Care; Pamidronate; Time and Motion Studies; Zoledronic Acid	2001
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. British journal of haematology, 2002, Volume: 116, Issue:2 Topics: Animals; Bone Marrow Cells; Bone Transplantation; Cell Division; Diphosphonates; Humans; Imidazoles; Mice; Mice, SCID; Multiple Myeloma; Osteoclasts; Pamidronate; Transplantation, Heterologous; Zoledronic Acid	2002
Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochemical and biophysical research communications, 2002, Mar-01, Volume: 291, Issue:3 Topics: Biomarkers; Cell Differentiation; Cells, Cultured; Collagen Type I; Dexamethasone; Diphosphonates; Dose-Response Relationship, Drug; Glucocorticoids; Glycoproteins; Humans; Imidazoles; Kinetics; Osteoblasts; Osteoprotegerin; Pamidronate; Protein Biosynthesis; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; RNA, Messenger; Transcriptional Activation; Zoledronic Acid	2002
Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. Journal of endocrinological investigation, 2002, Volume: 25, Issue:6 Topics: Adult; Aged; Alkaline Phosphatase; Cell Differentiation; Cell Division; Cell Survival; Cells, Cultured; Clodronic Acid; Collagen Type I; Culture Media; Culture Media, Serum-Free; Diphosphonates; Fetal Blood; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoblasts; Pamidronate; Zoledronic Acid	2002
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. The Journal of pharmacology and experimental therapeutics, 2002, Volume: 302, Issue:3 Topics: Angiogenesis Inhibitors; Apoptosis; Cell Adhesion; Cell Cycle; Cell Movement; Cells, Cultured; Chemotaxis; Chorion; Diphosphonates; Endothelial Growth Factors; Endothelium, Vascular; Fibroblast Growth Factor 2; Growth Substances; Humans; Image Cytometry; Imidazoles; Lymphokines; Muscle, Smooth, Vascular; Pamidronate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Zoledronic Acid	2002
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-01, Volume: 20, Issue:17 Topics: Clodronic Acid; Diphosphonates; Drug Monitoring; Humans; Imidazoles; Multiple Myeloma; Osteolysis; Pamidronate; Zoledronic Acid	2002
Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. British journal of haematology, 2002, Volume: 119, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pamidronate; Plasma Cells; Protein Prenylation; Tumor Cells, Cultured; Zoledronic Acid	2002
[Bisphosphonates in bone metastases. Fewer fractures, less pain]. MMW Fortschritte der Medizin, 2002, Sep-26, Volume: 144, Issue:39 Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Pain; Pamidronate; Zoledronic Acid	2002
Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. Pain, 2002, Volume: 100, Issue:3 Topics: Animals; Bone Density; Bone Neoplasms; Clodronic Acid; Diphosphonates; Female; Hyperalgesia; Hyperesthesia; Imidazoles; Models, Animal; Neoplasm Transplantation; Observer Variation; Pain; Pain Measurement; Pain Threshold; Pamidronate; Radiography; Rats; Rats, Sprague-Dawley; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Tibia; Touch; Treatment Outcome; Zoledronic Acid	2002
The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood, 2003, Sep-15, Volume: 102, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Division; Diphosphonates; Drug Synergism; Hematopoietic Stem Cells; HL-60 Cells; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, SCID; Monomeric GTP-Binding Proteins; Pamidronate; Piperazines; Protein Prenylation; Pyrimidines; Zoledronic Acid	2003
Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. The Journal of urology, 2003, Volume: 170, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Caspase 3; Caspases; Cell Membrane; Cell Survival; Diphosphonates; DNA Fragmentation; Humans; Imidazoles; Male; Mevalonic Acid; Pamidronate; Prostatic Neoplasms; Protein Prenylation; ras Proteins; Zoledronic Acid	2003
Bisphosphonates in prostate cancer: where are we and where should we go? Journal of the National Cancer Institute, 2003, Sep-03, Volume: 95, Issue:17 Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Male; Neoplasms, Hormone-Dependent; Osteoporosis; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zoledronic Acid	2003
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2003, Volume: 61, Issue:9 Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronate; Zoledronic Acid	2003
Cancer patients with bone complications prefer infusion of zoledronic acid. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:8 Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Multicenter Studies as Topic; Pamidronate; Patient Satisfaction; Time Factors; Zoledronic Acid	2003
Avascular necrosis of the jaws: risk factors in metastatic cancer patients. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2003, Volume: 61, Issue:10 Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Risk Factors; Zoledronic Acid	2003
Treatment strategies for myeloma bone disease. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:12 Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Orthopedic Procedures; Pamidronate; Zoledronic Acid	2003
Bisphosphonates and avascular necrosis of the jaws. Australian dental journal, 2003, Volume: 48, Issue:4 Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Tooth Extraction; Zoledronic Acid	2003
Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcified tissue international, 2004, Volume: 75, Issue:1 Topics: Alendronate; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Diphosphonates; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Flow Cytometry; Giant Cell Tumor of Bone; Humans; Imidazoles; In Situ Nick-End Labeling; Osteoclasts; Pamidronate; Stromal Cells; Tumor Cells, Cultured; Zoledronic Acid	2004
Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2004, Volume: 12, Issue:9 Topics: Bone Resorption; Breast Neoplasms; Diphosphonates; Drug Resistance; Female; Humans; Hypercalcemia; Imidazoles; Liver Neoplasms; Middle Aged; Neoplasm Metastasis; Pamidronate; Quality of Life; Recurrence; Zoledronic Acid	2004
Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy. Acta radiologica (Stockholm, Sweden : 1987), 2004, Volume: 45, Issue:1 Topics: Adult; Aged; Anastrozole; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Letrozole; Magnetic Resonance Imaging; Middle Aged; Nitriles; Pamidronate; Pilot Projects; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid	2004
Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells. British journal of cancer, 2004, Aug-16, Volume: 91, Issue:4 Topics: Antimetabolites; Antineoplastic Agents; Cell Cycle; Clodronic Acid; Diphosphonates; Disease Progression; Humans; Imidazoles; Melanoma; Nitrogen; Pamidronate; Skin Neoplasms; Tumor Cells, Cultured; Zoledronic Acid	2004
The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene, 2004, Sep-09, Volume: 23, Issue:41 Topics: Alkyl and Aryl Transferases; Apoptosis; Caspases; Cell Division; Diphosphonates; Drug Synergism; Enzyme Inhibitors; Epidermal Growth Factor; Farnesyltranstransferase; Humans; Imidazoles; KB Cells; Mitogen-Activated Protein Kinases; Pamidronate; Protein Prenylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinolones; Zoledronic Acid	2004
Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis. Clinical orthopaedics and related research, 2004, Issue:426 Topics: Annexin A5; Apoptosis; Bone Neoplasms; Caspase 3; Caspases; Diphosphonates; Dose-Response Relationship, Drug; Flow Cytometry; Giant Cell Tumor of Bone; Humans; Imidazoles; Immunohistochemistry; Pamidronate; Poly Adenosine Diphosphate Ribose; Tumor Cells, Cultured; Zoledronic Acid	2004
Intravenous bisphosphonates and osteonecrosis. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2004, Volume: 98, Issue:3 Topics: Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Interdisciplinary Communication; Jaw Diseases; Osteolysis; Osteonecrosis; Pamidronate; Zoledronic Acid	2004
In vitro toxicity of bisphosphonates on human neuroblastoma cell lines. Anti-cancer drugs, 2004, Volume: 15, Issue:8 Topics: Alendronate; Apoptosis; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Diphosphonates; Drug Screening Assays, Antitumor; Germany; Humans; Ibandronic Acid; Imidazoles; Neuroblastoma; Pamidronate; Time Factors; Zoledronic Acid	2004
Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Journal of the National Cancer Institute, 2005, Jan-05, Volume: 97, Issue:1 Topics: Analgesics; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Jaw; Male; Necrosis; Osteomyelitis; Osteopetrosis; Pain; Pain Measurement; Pamidronate; Prostatic Neoplasms; Quality of Life; Research Design; Surveys and Questionnaires; Time Factors; Treatment Outcome; Zoledronic Acid	2005
Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. American journal of clinical oncology, 2005, Volume: 28, Issue:1 Topics: Ambulatory Care; Bone Neoplasms; Breast Neoplasms; Costs and Cost Analysis; Diphosphonates; Female; Hospitalization; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid	2005
[Rapid drug information]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2005, Volume: 48, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Information Services; Germany; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Osteoporosis; Pamidronate; Risk Assessment; Zoledronic Acid	2005
The issue of renal safety of zoledronic acid from a nephrologist's point of view. The oncologist, 2005, Volume: 10, Issue:5 Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid	2005
"Safety and convenience of a 15-minute infusion of zoledronic acid": not so safe. The oncologist, 2005, Volume: 10, Issue:5 Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid	2005
Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2005, Volume: 13, Issue:12 Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Neoplasm Metastasis; Pamidronate; Quality of Life; State Medicine; United Kingdom; Zoledronic Acid	2005
Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations. Biological trace element research, 2005, Volume: 104, Issue:2 Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Resorption; Cations, Divalent; Diphosphonates; Imidazoles; Isoenzymes; Magnesium; Osteoblasts; Osteosarcoma; Pamidronate; Rats; Tumor Cells, Cultured; Zinc; Zoledronic Acid	2005
Bisphosphonates, cancer, and osteonecrosis--a single practice experience. Delaware medical journal, 2005, Volume: 77, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Debridement; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Neoplasms; Osteonecrosis; Pamidronate; Zoledronic Acid	2005
Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK. Current medical research and opinion, 2005, Volume: 21, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Calcium Metabolism Disorders; Chemoprevention; Cost-Benefit Analysis; Decision Support Techniques; Diphosphonates; Female; Health Care Costs; Humans; Imidazoles; Middle Aged; Pamidronate; State Medicine; United Kingdom; Zoledronic Acid	2005
Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update. Medicina oral, patologia oral y cirugia bucal, 2005, Jul-01, Volume: 10 Suppl 2 Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid	2005
Osteonecrosis of the jaw and bisphosphonates. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Breast Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Pamidronate; Risk Factors; Zoledronic Acid	2005
Osteonecrosis of the jaw and bisphosphonates. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Alendronate; Animals; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid	2005
Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer. BMC cancer, 2005, Jul-28, Volume: 5 Topics: Aged; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Disease Progression; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Pamidronate; Retrospective Studies; Time Factors; Treatment Outcome; Zoledronic Acid	2005
Studies in osteonecrosis. British dental journal, 2005, Aug-27, Volume: 199, Issue:4 Topics: Antineoplastic Agents; Diphosphonates; Humans; Imidazoles; Osteonecrosis; Pamidronate; Zoledronic Acid	2005
Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. Journal of endodontics, 2005, Volume: 31, Issue:10 Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Pamidronate; Zoledronic Acid	2005
Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. Clinical therapeutics, 2005, Volume: 27, Issue:8 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Pamidronate; Quality-Adjusted Life Years; United Kingdom; Zoledronic Acid	2005
Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2005, Volume: 34, Issue:10 Topics: Aged; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Curettage; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Recurrence; Zoledronic Acid	2005
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2005, Volume: 63, Issue:11 Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Dental Caries; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hyperostosis; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Osteopetrosis; Osteoporosis; Pamidronate; Periodontitis; Prostatic Neoplasms; Risk Factors; Tooth Extraction; Zoledronic Acid	2005
Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma. Internal medicine journal, 2005, Volume: 35, Issue:12 Topics: Acute Kidney Injury; Aged; Bone Density Conservation Agents; Calcitriol; Calcium Carbonate; Diphosphonates; Fatal Outcome; Female; Humans; Hypocalcemia; Imidazoles; Injections, Intravenous; Magnesium Deficiency; Male; Middle Aged; Multiple Myeloma; Pamidronate; Zoledronic Acid	2005
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Greece; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prospective Studies; Prostatic Neoplasms; Risk Factors; Time Factors; Treatment Failure; Zoledronic Acid	2005
[Bisphosphonates-related jaw osteonecrosis]. Presse medicale (Paris, France : 1983), 2005, Sep-10, Volume: 34, Issue:15 Topics: Adolescent; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Pamidronate; Radiography, Panoramic; Radionuclide Imaging; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid	2005
Consumer groups look to improve adverse event reporting systems. Journal of the National Cancer Institute, 2005, Dec-21, Volume: 97, Issue:24 Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Bone Density Conservation Agents; Consumer Behavior; Diphosphonates; Drug Approval; Humans; Imidazoles; Multiple Myeloma; Osteonecrosis; Pamidronate; Product Surveillance, Postmarketing; United States; United States Food and Drug Administration; Zoledronic Acid	2005
Osteonecrosis of the jaws and bisphosphonates. Report of three cases. Medicina oral, patologia oral y cirugia bucal, 2006, Jan-01, Volume: 11, Issue:1 Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Tooth Extraction; Zoledronic Acid	2006
[Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates]. Mund-, Kiefer- und Gesichtschirurgie : MKG, 2005, Volume: 9, Issue:4 Topics: Aged; Alendronate; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Mouth Diseases; Osteonecrosis; Osteoporosis, Postmenopausal; Pamidronate; Plasmacytoma; Radiography, Panoramic; Risk Factors; Zoledronic Acid	2005
By the way, doctor. I've heard that taking Fosamax for a long time causes the jawbone to deteriorate. Do you know anything about this? Harvard women's health watch, 2005, Volume: 13, Issue:4 Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Osteoclasts; Osteonecrosis; Pamidronate; Zoledronic Acid	2005
Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications. The New Zealand dental journal, 2006, Volume: 102, Issue:1 Topics: Adenocarcinoma; Aged, 80 and over; Bone Density Conservation Agents; Carcinoma; Diabetes Mellitus, Type 2; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Patient Care Planning; Tooth Extraction; Zoledronic Acid	2006
Relationship between periodontal disease and systemic diseases. Texas dental journal, 2006, Volume: 123, Issue:2 Topics: Alendronate; Bone Density Conservation Agents; Contraindications; Dental Implantation, Endosseous; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Osteonecrosis; Pamidronate; Zoledronic Acid	2006
Differential effects of bisphosphonates on breast cancer cell lines. Cancer letters, 2007, Feb-08, Volume: 246, Issue:1-2 Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cyclin D1; Diphosphonates; DNA Fragmentation; Etidronic Acid; Female; Flow Cytometry; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Risedronic Acid; RNA, Messenger; Zoledronic Acid	2007
The buzz about bisphosphonates. LDA journal, 2005,Fall, Volume: 64, Issue:3 Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Zoledronic Acid	2005
Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias. Medical oncology (Northwood, London, England), 2006, Volume: 23, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteomyelitis; Osteonecrosis; Pamidronate; Paraproteinemias; Zoledronic Acid	2006
Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. International journal of oral and maxillofacial surgery, 2006, Volume: 35, Issue:7 Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Retrospective Studies; Tooth Extraction; Zoledronic Acid	2006
Bisphosphonate-associated arthritis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2006, Volume: 12, Issue:3 Topics: Arthritis; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Fatal Outcome; Female; Humans; Hypercalcemia; Imidazoles; Infusions, Intravenous; Middle Aged; Pamidronate; Zoledronic Acid	2006
[Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis]. Ugeskrift for laeger, 2006, May-22, Volume: 168, Issue:21 Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Pamidronate; Zoledronic Acid	2006
In vitro inhibition of matrix metalloproteinase activity in tracheal epithelial lining fluid from horses with recurrent airway obstruction. American journal of veterinary research, 2006, Volume: 67, Issue:7 Topics: Airway Obstruction; Animals; Collagen Type I; Diphosphonates; Gelatin; Horse Diseases; Horses; Imidazoles; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Pamidronate; Respiratory Mucosa; Tetracyclines; Trachea; Zoledronic Acid	2006
Drug induced osteonecrosis of the jaws. The Journal of the Tennessee Dental Association, 2006,Spring, Volume: 86, Issue:2 Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Osteoclasts; Osteomyelitis; Osteonecrosis; Pamidronate; Splints; Zoledronic Acid	2006
Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clinic proceedings, 2006, Volume: 81, Issue:8 Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Oral Surgical Procedures; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid	2006
Case studies in metastatic bone disease: understanding the unique nature of bone loss due to malignancy. ONS news, 2006, Volume: 21, Issue:8 Suppl Topics: Aftercare; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Early Diagnosis; Humans; Imidazoles; Nurse's Role; Nursing Assessment; Oncology Nursing; Pamidronate; Patient Care Planning; Patient Education as Topic; Quality of Life; Risk Assessment; Vitamin D; Zoledronic Acid	2006
Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wiener klinische Wochenschrift, 2006, Volume: 118, Issue:15-16 Topics: Adult; Aged; Biopsy; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Histiocytosis, Langerhans-Cell; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Magnetic Resonance Imaging; Male; Mandible; Mandibular Diseases; Maxilla; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Radiography, Panoramic; Radionuclide Imaging; Retrospective Studies; Risk Factors; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid	2006
Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines. The Journal of urology, 2006, Volume: 176, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Death; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Pamidronate; Tumor Cells, Cultured; Zoledronic Acid	2006
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma. The Lancet. Oncology, 2006, Volume: 7, Issue:11 Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid	2006
Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2006, Volume: 12, Issue:4 Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Creatinine; Diphosphonates; Drug Administration Schedule; Drug Costs; Female; Health Care Costs; Humans; Imidazoles; Infusions, Intravenous; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Pamidronate; Prevalence; Registries; Retrospective Studies; Treatment Outcome; Zoledronic Acid	2006
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta haematologica, 2007, Volume: 117, Issue:3 Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Mandible; Maxilla; Middle Aged; Multiple Myeloma; Necrosis; Osteonecrosis; Pamidronate; Tomography, X-Ray Computed; Zoledronic Acid	2007
[Osteonecrosis associated with the use of biphosphonates: Case report]. Revista medica de Chile, 2006, Volume: 134, Issue:9 Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Pamidronate; Zoledronic Acid	2006
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta bio-medica : Atenei Parmensis, 2006, Volume: 77, Issue:2 Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conservation Agents; Bone Neoplasms; Chlorhexidine; Curettage; Diphosphonates; Female; Humans; Hydrogen Peroxide; Imidazoles; Jaw Diseases; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Mouthwashes; Multiple Myeloma; Osteonecrosis; Osteoporosis; Pamidronate; Radiography; Time Factors; Zoledronic Acid	2006
I'm taking bisphosphonates for my osteoporosis, but I've heard it can cause a serious jaw condition. Is this something I should be concerned about? DukeMedicine healthnews, 2006, Volume: 12, Issue:11 Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Zoledronic Acid	2006
Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone, 2007, Volume: 40, Issue:4 Topics: Adult; Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Pamidronate; Risk Factors; Switzerland; Time Factors; Zoledronic Acid	2007
Outcomes of patients with prostate cancer receiving zoledronic acid or pamidronate for prevention of skeletal-related events. Pharmacotherapy, 2007, Volume: 27, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cohort Studies; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Pamidronate; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome; Zoledronic Acid	2007
Morphoproteomic expression of H-ras (p21ras) correlates with serum monoclonal immunoglobulin reduction in multiple myeloma patients following pamidronate treatment. Annals of clinical and laboratory science, 2007,Winter, Volume: 37, Issue:1 Topics: Alkyl and Aryl Transferases; Biomarkers; Cell Proliferation; Diphosphonates; Farnesyltranstransferase; Humans; Imidazoles; Immunoglobulin A; Immunoglobulin G; Immunohistochemistry; Multiple Myeloma; Pamidronate; Pennsylvania; Proto-Oncogene Proteins p21(ras); Zoledronic Acid	2007
Use of intravenous bisphosphonates in osteoporosis. Current osteoporosis reports, 2007, Volume: 5, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Patient Compliance; Zoledronic Acid	2007
Bisphosphonates and jaw osteonecrosis: the UAMS experience. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 136, Issue:3 Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Bone Density Conservation Agents; Curettage; Dental Care; Diphosphonates; Female; Humans; Hyperbaric Oxygenation; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Retrospective Studies; Time Factors; Treatment Outcome; Zoledronic Acid	2007
[Cost analysis of tumor-induced osteolysis treated with intravenous zoledronic acid and pamidronate: a time-motion study]. Recenti progressi in medicina, 2007, Volume: 98, Issue:1 Topics: Bone Density Conservation Agents; Costs and Cost Analysis; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Neoplasms; Osteolysis; Pamidronate; Time and Motion Studies; Zoledronic Acid	2007
A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia, 2007, Volume: 21, Issue:7 Topics: Aged; Diphosphonates; Drug Administration Schedule; Drug Evaluation; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Retrospective Studies; Risk Factors; Zoledronic Acid	2007
Bisphosphonates and osteonecrosis of the jaw. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:7 Topics: Bone Remodeling; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Neoplasms; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid	2007
An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting. Current medical research and opinion, 2007, Volume: 23, Issue:7 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Hospitals; Humans; Imidazoles; Infusions, Intravenous; Medical Audit; Pamidronate; Time Factors; United Kingdom; Zoledronic Acid	2007
The role of surgery in jaw bone necrosis associated with long-term use of bisphosphonates. Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:3 Topics: Adenocarcinoma; Bone Neoplasms; Bone Plates; Bone Screws; Breast Neoplasms; Cutaneous Fistula; Diphosphonates; Female; Humans; Imidazoles; Male; Mandible; Mandibular Diseases; Middle Aged; Necrosis; Oral Fistula; Osteolysis; Osteomyelitis; Pamidronate; Prostatic Neoplasms; Recurrence; Tomography, X-Ray Computed; Zoledronic Acid	2008
Treating bisphosphonate osteonecrosis of the jaws: is there a role for resection and vascularized reconstruction? Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2007, Volume: 65, Issue:11 Topics: Bone Density Conservation Agents; Bone Plates; Bone Transplantation; Breast Neoplasms; Carcinoma; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Mandibular Diseases; Middle Aged; Osteonecrosis; Pamidronate; Plastic Surgery Procedures; Surgical Flaps; Zoledronic Acid	2007
Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint bone spine, 2008, Volume: 75, Issue:1 Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Middle Aged; Multiple Myeloma; Orthognathic Surgical Procedures; Osteonecrosis; Osteoporosis; Pamidronate; Prospective Studies; Zoledronic Acid	2008
NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model. Journal of the American Chemical Society, 2008, Jan-30, Volume: 130, Issue:4 Topics: Alendronate; Biochemistry; Bone and Bones; Bone Density Conservation Agents; Crystallography, X-Ray; Diphosphonates; Etidronic Acid; Humans; Hydrogen; Imidazoles; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Pamidronate; Protein Structure, Tertiary; Risedronic Acid; Zoledronic Acid	2008
Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children? Clinical endocrinology, 2008, Volume: 68, Issue:6 Topics: Adolescent; Bone Density Conservation Agents; Child; Cohort Studies; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Oral Surgical Procedures; Osteonecrosis; Pamidronate; Zoledronic Acid	2008
"Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2008, Volume: 36, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Neoplasms; Oral Surgical Procedures; Osteonecrosis; Pamidronate; Retrospective Studies; Risk Factors; Surveys and Questionnaires; Zoledronic Acid	2008
Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2008, Volume: 105, Issue:3 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw; Jaw Diseases; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Tomography, Spiral Computed; Tooth Extraction; Water; Zoledronic Acid	2008
Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. Toxicology in vitro : an international journal published in association with BIBRA, 2008, Volume: 22, Issue:4 Topics: Animals; Bone Density Conservation Agents; Cell Line; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Geranyltranstransferase; Humans; Ibandronic Acid; Imidazoles; Inhibitory Concentration 50; Kidney; Male; Pamidronate; Rats; Rats, Sprague-Dawley; RNA, Messenger; Zoledronic Acid	2008
Bisphosphonates induce apoptosis in CLL cells independently of MDR phenotype. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Diphosphonates; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Flow Cytometry; Genes, MDR; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pamidronate; Phenotype; Zoledronic Acid	2008
Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2008, Volume: 66, Issue:4 Topics: Age Factors; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Case-Control Studies; Confounding Factors, Epidemiologic; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Logistic Models; Male; Multivariate Analysis; Neoplasms; Obesity; Osteonecrosis; Pamidronate; Risk Factors; Smoking; Zoledronic Acid	2008
Osteonecrosis of the jaw. Journal of the American Dental Association (1939), 2008, Volume: 139, Issue:4 Topics: Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis, Postmenopausal; Pamidronate; Time Factors; Zoledronic Acid	2008
[Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies]. Recenti progressi in medicina, 2008, Volume: 99, Issue:1 Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Pamidronate; Zoledronic Acid	2008
Paget's disease and bisphosphonate-associated osteonecrosis of the jaws. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2008, Volume: 66, Issue:6 Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Male; Maxillary Diseases; Osteitis Deformans; Osteonecrosis; Pamidronate; Zoledronic Acid	2008
Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report. International journal of urology : official journal of the Japanese Urological Association, 2008, Volume: 15, Issue:6 Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pamidronate; Zoledronic Acid	2008
Use of intravenous bisphosphonates in older women with breast cancer. The oncologist, 2008, Volume: 13, Issue:5 Topics: Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Injections, Intravenous; Multivariate Analysis; Pain; Pamidronate; Prevalence; SEER Program; Survival Rate; United States; Zoledronic Acid	2008
Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2008, Volume: 16, Issue:11 Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Health Knowledge, Attitudes, Practice; Humans; Imidazoles; Incidence; Italy; Jaw Diseases; Male; Osteonecrosis; Pamidronate; Retrospective Studies; Risk Factors; Zoledronic Acid	2008
Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. The oncologist, 2008, Volume: 13, Issue:8 Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw; Jaw Neoplasms; Male; Mandible; Maxilla; Osteonecrosis; Pamidronate; Retrospective Studies; Risk Factors; Treatment Outcome; Zoledronic Acid	2008
Clinical and radiologic response in patients with bone metastases managed with combined radiotherapy and bisphosphonates. Journal of surgical oncology, 2008, Dec-01, Volume: 98, Issue:7 Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Osteogenesis; Pain Measurement; Pamidronate; Radiotherapy, Adjuvant; Zoledronic Acid	2008
Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells. European journal of pharmacology, 2008, Dec-14, Volume: 600, Issue:1-3 Topics: 3T3 Cells; Alendronate; Animals; Bone Density Conservation Agents; Calcium; Calcium Channels, L-Type; Cattle; Cell Line; Diabetes Complications; Diphosphonates; Dose-Response Relationship, Drug; Glycation End Products, Advanced; Imidazoles; Mice; Osteoblasts; Osteoporosis; Pamidronate; Rats; Reactive Oxygen Species; Serum Albumin, Bovine; Time Factors; Zoledronic Acid	2008
Inhibition of osteoblast function in vitro by aminobisphosphonates. Journal of cellular biochemistry, 2009, Jan-01, Volume: 106, Issue:1 Topics: Alkaline Phosphatase; Animals; Bone Density Conservation Agents; Cell Differentiation; Cell Proliferation; Cells, Cultured; Diphosphonates; Imidazoles; Osteoblasts; Osteogenesis; Pamidronate; Rats; Zoledronic Acid	2009
[Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma]. Ugeskrift for laeger, 2009, Jan-05, Volume: 171, Issue:1-2 Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw; Multiple Myeloma; Oral Hygiene; Osteonecrosis; Pamidronate; Risk Factors; Zoledronic Acid	2009
The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats. Biomaterials, 2009, Volume: 30, Issue:9 Topics: Absorptiometry, Photon; Animals; Biomechanical Phenomena; Bone Density; Coated Materials, Biocompatible; Diphosphonates; Durapatite; Female; Ibandronic Acid; Imidazoles; Implants, Experimental; Microscopy, Electron, Scanning; Ovariectomy; Pamidronate; Rats; Rats, Sprague-Dawley; Surface Properties; Tibia; Titanium; X-Ray Microtomography; Zoledronic Acid	2009
Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2009, Volume: 67, Issue:4 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Angiogenesis Inhibitors; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bone Density Conservation Agents; Diabetes Mellitus, Type 2; Diphosphonates; Female; Follow-Up Studies; Glucocorticoids; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Minimally Invasive Surgical Procedures; Oral Surgical Procedures; Osteonecrosis; Pamidronate; Risk Factors; Smoking; Time Factors; Treatment Outcome; Wound Healing; Zoledronic Acid	2009
Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2009, Volume: 67, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Pamidronate; Treatment Outcome; Zoledronic Acid	2009
Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells. Anticancer research, 2009, Volume: 29, Issue:4 Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Cell Proliferation; Coculture Techniques; Diphosphonates; Humans; Imidazoles; Luciferases; Male; Mice; Osteoblasts; Osteoclasts; Pamidronate; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcriptional Activation; Tumor Cells, Cultured; Zoledronic Acid	2009
Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy? European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:11 Topics: Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid	2009
Paget's disease of bone and osteonecrosis. Dental update, 2009, Volume: 36, Issue:3 Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Dry Socket; Female; Humans; Hypercementosis; Imidazoles; Injections, Intravenous; Maxillary Diseases; Osteitis Deformans; Osteonecrosis; Pamidronate; Skull; Tooth Extraction; Tooth Socket; Zoledronic Acid	2009
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2009, Volume: 67, Issue:7 Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Early Diagnosis; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Pamidronate; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Technetium Compounds; Zoledronic Acid	2009
Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clinical oral investigations, 2010, Volume: 14, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Connective Tissue; Diphosphonates; Female; Humans; Imidazoles; Inflammation; Jaw; Jaw Diseases; Male; Mandibular Diseases; Maxillary Diseases; Microscopy, Electron, Scanning; Middle Aged; Osteomyelitis; Osteonecrosis; Osteoporosis; Osteoradionecrosis; Pamidronate; Time Factors; Zoledronic Acid	2010
A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm. The Annals of pharmacotherapy, 2009, Volume: 43, Issue:9 Topics: Aged; Algorithms; Bone Density Conservation Agents; Calcitonin; Carcinoma, Transitional Cell; Crystalloid Solutions; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Isotonic Solutions; Male; Neoplasm Metastasis; Pamidronate; Ureteral Neoplasms; Zoledronic Acid	2009
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-10, Volume: 27, Issue:32 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Greece; Humans; Ibandronic Acid; Imidazoles; Incidence; Jaw Diseases; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Risk Factors; Zoledronic Acid	2009
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer. Cancer investigation, 2009, Volume: 27, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Jaw Diseases; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Retrospective Studies; Spinal Cord Compression; Time Factors; Treatment Outcome; Zoledronic Acid	2009
Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clinical oral investigations, 2011, Volume: 15, Issue:1 Topics: Analysis of Variance; Apoptosis; Bone Density Conservation Agents; Cell Movement; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelial Cells; Endothelium, Vascular; Humans; Ibandronic Acid; Imidazoles; Leukocytes, Mononuclear; Neovascularization, Physiologic; Pamidronate; Statistics, Nonparametric; Stem Cells; Umbilical Veins; Zoledronic Acid	2011
Jaw bone changes in rats after treatment with zoledronate and pamidronate. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2010, Volume: 109, Issue:3 Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Femur; Imidazoles; Inflammation; Mandible; Osteonecrosis; Pamidronate; Rats; Rats, Sprague-Dawley; Single-Blind Method; Time Factors; Zoledronic Acid	2010
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2010, Volume: 68, Issue:5 Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, External; Etidronic Acid; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Inflammation Mediators; Injections, Intraperitoneal; Injections, Subcutaneous; Interleukin-1; Male; Mice; Mice, Inbred BALB C; Necrosis; Osteonecrosis; Osteosclerosis; Pamidronate; Pravastatin; Radionuclide Imaging; Radiopharmaceuticals; Risedronic Acid; Technetium; Tibia; Time Factors; Zoledronic Acid	2010
An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem, 2010, May-03, Volume: 5, Issue:5 Topics: Alendronate; Anabolic Agents; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Drug Delivery Systems; Durapatite; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Nuclear Magnetic Resonance, Biomolecular; Pamidronate; Risedronic Acid; Zoledronic Acid	2010
Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2010, Volume: 109, Issue:5 Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Diphosphonates; Dry Socket; Female; Humans; Imaging, Three-Dimensional; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Oroantral Fistula; Osteonecrosis; Osteosclerosis; Pamidronate; Radiography, Dental, Digital; Radiography, Panoramic; Tooth Socket; Zoledronic Acid	2010
Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia, 2010, Volume: 24, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Diseases; Clinical Trials, Phase III as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Osteolysis; Pamidronate; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid	2010
Initial results of the treatment of diffuse sclerosing osteomyelitis of the mandible with bisphosphonates. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2011, Volume: 39, Issue:1 Topics: Adult; Aged; Analgesics; Bone Density Conservation Agents; Child; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Male; Mandibular Diseases; Middle Aged; Osteomyelitis; Pamidronate; Radionuclide Imaging; Recurrence; Sclerosis; Treatment Outcome; Young Adult; Zoledronic Acid	2011
Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2010, Volume: 110, Issue:1 Topics: Aged; Alcohol Drinking; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Chronic Disease; Clindamycin; Cohort Studies; Combined Modality Therapy; Debridement; Diphosphonates; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Jaw Diseases; Male; Oral Fistula; Osteonecrosis; Pamidronate; Penicillins; Prospective Studies; Remission Induction; Risk Factors; Smoking; Tooth Extraction; Treatment Outcome; Wound Healing; Zoledronic Acid	2010
Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. American journal of therapeutics, 2011, Volume: 18, Issue:5 Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Liver Cirrhosis, Biliary; Male; Middle Aged; Osteoporosis; Pamidronate; Retrospective Studies; Zoledronic Acid	2011
Bisphosphonate protonation states, conformations, and dynamics on bone mineral probed by solid-state NMR without isotope enrichment. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2010, Volume: 76, Issue:1 Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Crystallization; Diphosphonates; Horses; Imidazoles; Magnetic Resonance Spectroscopy; Molecular Structure; Pamidronate; Structure-Activity Relationship; Technology, Pharmaceutical; Zoledronic Acid	2010
Bisphosphonates for bone pain #113. Journal of palliative medicine, 2010, Volume: 13, Issue:7 Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Neoplasms; Pain; Pamidronate; Renal Insufficiency; Zoledronic Acid	2010
Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro. Oral diseases, 2011, Volume: 17, Issue:2 Topics: Apoptosis; Bone Density Conservation Agents; Cell Culture Techniques; Cell Movement; Cell Survival; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelial Cells; Endothelium, Vascular; Fibroblasts; Fluoresceins; Fluorescent Dyes; Humans; Ibandronic Acid; Imidazoles; In Situ Nick-End Labeling; Nitrogen; Osteoblasts; Pamidronate; Umbilical Veins; Zoledronic Acid	2011
Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. The oncologist, 2010, Volume: 15, Issue:11 Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw; Male; Osteonecrosis; Pamidronate; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid	2010
Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells. Cancer immunity, 2010, Nov-12, Volume: 10 Topics: Bone Density Conservation Agents; Breast Neoplasms; Cell Line, Tumor; Cytotoxicity, Immunologic; Diphosphonates; Female; Humans; Imidazoles; Immunotherapy, Adoptive; Lymphocyte Activation; Pamidronate; T-Lymphocyte Subsets; T-Lymphocytes; Zoledronic Acid	2010
Zoledronic acid in myeloma: MRC Myeloma IX. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Administration, Oral; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Drug Administration Schedule; Humans; Imidazoles; Infusions, Intravenous; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zoledronic Acid	2010
The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study. Clinical oral investigations, 2012, Volume: 16, Issue:1 Topics: Apoptosis; Bone Density Conservation Agents; Cell Culture Techniques; Cell Line; Cell Movement; Cell Proliferation; Cell Survival; Clodronic Acid; Coloring Agents; Diphosphonates; Fluoresceins; Fluorescent Dyes; Humans; Ibandronic Acid; Imidazoles; In Situ Nick-End Labeling; Keratinocytes; Mouth Mucosa; Pamidronate; Tetrazolium Salts; Thiazoles; Zoledronic Acid	2012
Inhibition of the isoprenoid biosynthesis pathway; detection of intermediates by UPLC-MS/MS. Biochimica et biophysica acta, 2011, Volume: 1811, Issue:4 Topics: Alkyl and Aryl Transferases; Bone Density Conservation Agents; Bridged Bicyclo Compounds, Heterocyclic; Chromatography, Liquid; Diphosphonates; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Farnesyltranstransferase; Fibroblasts; Hep G2 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Lymphocytes; Mevalonic Acid; Pamidronate; Prenylation; Signal Transduction; Tandem Mass Spectrometry; Terpenes; Tricarboxylic Acids; Zoledronic Acid	2011
American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-20, Volume: 29, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Pamidronate; RANK Ligand; Societies, Medical; Survival Rate; Treatment Outcome; Zoledronic Acid	2011
Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment. Oral diseases, 2011, Volume: 17, Issue:4 Topics: Alkaline Phosphatase; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein 4; Bone Remodeling; Cell Count; Diphosphonates; Fibroblasts; Humans; Imidazoles; Immunohistochemistry; Jaw Diseases; MSX1 Transcription Factor; Osteoblasts; Osteocytes; Osteonecrosis; Osteopetrosis; Pamidronate; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Zoledronic Acid	2011
Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. International journal of oral and maxillofacial surgery, 2011, Volume: 40, Issue:6 Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Bone Density Conservation Agents; Cohort Studies; Collagen Type I; Collagen Type I, alpha 1 Chain; Cytochrome P-450 CYP2C8; Diphosphonates; Female; Gene Frequency; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Matrix Metalloproteinase 2; Middle Aged; Multiple Myeloma; Osteonecrosis; Osteopontin; Osteoprotegerin; Pamidronate; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Receptor Activator of Nuclear Factor-kappa B; Risk Factors; Smoking; Time Factors; Tumor Necrosis Factor-alpha; Zoledronic Acid	2011
Pamidronate and zoledronate effects in the increment of bone mineral density and histomorphometry in rats. Acta cirurgica brasileira, 2011, Volume: 26, Issue:2 Topics: Animals; Bone Density; Bone Density Conservation Agents; Densitometry; Dietary Proteins; Diphosphonates; Female; Imidazoles; Malnutrition; Ovariectomy; Pamidronate; Random Allocation; Rats; Rats, Inbred Lew; Zoledronic Acid	2011
[Prosthetic rehabilitation after osteonecrosis of the jaws due to histiocytosis X and treatment with bisphosphonates apropos of a case]. Odonto-stomatologie tropicale = Tropical dental journal, 2010, Volume: 33, Issue:132 Topics: Adult; Alendronate; Bone Density Conservation Agents; Denture Design; Denture, Partial, Fixed; Denture, Partial, Temporary; Diphosphonates; Female; Histiocytosis, Langerhans-Cell; Humans; Imidazoles; Jaw, Edentulous, Partially; Mandibular Diseases; Osteonecrosis; Pamidronate; Risk Factors; Tooth Extraction; Zoledronic Acid	2010
Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2011, Volume: 112, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density Conservation Agents; Cariostatic Agents; Chlorhexidine; Dental Prophylaxis; Diphosphonates; Female; Fluorides; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Longitudinal Studies; Male; Middle Aged; Neoplasms; Oral Hygiene; Osteonecrosis; Pain Measurement; Pamidronate; Prospective Studies; Treatment Outcome; Zoledronic Acid	2011
DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by γδ T lymphocytes. Blood, 2011, Sep-08, Volume: 118, Issue:10 Topics: Antigen-Presenting Cells; Bone Density Conservation Agents; Caspase 1; Cells, Cultured; Dendritic Cells; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Immunomagnetic Separation; Interferon-gamma; Interleukin-18; Interleukin-1beta; Interleukin-2; Killer Cells, Natural; Leukocytes, Mononuclear; Lymphocyte Activation; Pamidronate; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid	2011
Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab. Clinical breast cancer, 2011, Volume: 11, Issue:4 Topics: Adult; Aged; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Middle Aged; Neoplasm Metastasis; Osteonecrosis; Pamidronate; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid	2011
Zoledronate and pamidronate depress neutrophil functions and survival in mice. British journal of pharmacology, 2012, Volume: 165, Issue:2 Topics: Animals; Bone Density Conservation Agents; Cell Differentiation; Cell Survival; Chemotaxis, Leukocyte; Diphosphonates; Imidazoles; Leukocyte Count; Mice; Mice, Inbred C57BL; NADPH Oxidases; Neutrophils; Pamidronate; Zoledronic Acid	2012
Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer. Immunotherapy, 2011, Volume: 3, Issue:7 Topics: Adjuvants, Immunologic; Antineoplastic Agents, Alkylating; B7-H1 Antigen; Cancer Vaccines; Clonal Anergy; Cyclophosphamide; Dendritic Cells; Diphosphonates; Female; Humans; Imidazoles; Immunosuppression Therapy; Immunotherapy, Active; Indoleamine-Pyrrole 2,3,-Dioxygenase; Macrophages; Neoplasms; Ovarian Neoplasms; Pamidronate; T-Lymphocytes, Regulatory; Th17 Cells; V-Set Domain-Containing T-Cell Activation Inhibitor 1; Zoledronic Acid	2011
Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2011, Volume: 69, Issue:10 Topics: Actins; Apoptosis; Becaplermin; Bone Density Conservation Agents; Caspase 3; Cell Adhesion; Cell Culture Techniques; Cell Movement; Cell Proliferation; Diphosphonates; Diterpenes; Fibroblasts; Gingiva; Humans; Imidazoles; In Situ Nick-End Labeling; Pamidronate; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Recombinant Proteins; Wound Healing; Zoledronic Acid	2011
[Inflammation of the jaws during treatment with bisphosphonates]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:41 Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Drug Approval; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Opportunistic Infections; Osteomyelitis; Osteonecrosis; Osteoporosis; Pamidronate; Practice Guidelines as Topic; Risk Factors; Zoledronic Acid	2011
The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2012, Volume: 40, Issue:8 Topics: Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Chromatography, High Pressure Liquid; Collagen Type I; Coloring Agents; Diphosphates; Diphosphonates; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Follow-Up Studies; Gingiva; Humans; Imidazoles; Osteoblasts; Osteocalcin; Osteosarcoma; Pamidronate; Tetrazolium Salts; Thiazoles; Zoledronic Acid	2012
Incidence of maxillary sinusitis and oro-antral fistulae in bisphosphonate-related osteonecrosis of the jaw. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2012, Volume: 40, Issue:7 Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Maxillary Diseases; Maxillary Sinusitis; Oroantral Fistula; Pamidronate; Radiography, Panoramic; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid	2012
Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases. Cancer, 2012, Apr-15, Volume: 118, Issue:8 Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Middle Aged; Pamidronate; Retrospective Studies; Zoledronic Acid	2012
Cutting edge: nitrogen bisphosphonate-induced inflammation is dependent upon mast cells and IL-1. Journal of immunology (Baltimore, Md. : 1950), 2012, Apr-01, Volume: 188, Issue:7 Topics: Alendronate; Animals; Chemotaxis; Clodronic Acid; Diphosphonates; Imidazoles; Interleukin-1alpha; Interleukin-1beta; Leukocytes; Mast Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Mutant Strains; Myeloid Differentiation Factor 88; Neutrophils; Pamidronate; Peritonitis; Receptors, Interleukin-1; Zoledronic Acid	2012
Osteopathology induced by bisphosphonates and dental implants: clinical observations. Clinical oral investigations, 2013, Volume: 17, Issue:1 Topics: Actinomycosis; Administration, Intravenous; Administration, Oral; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Debridement; Dental Implants; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Male; Mandible; Mandibular Neoplasms; Maxilla; Neoplasms; Osteomyelitis; Osteoporosis; Pamidronate; Risk Factors; Time Factors; Zoledronic Acid	2013
Coercing bisphosphonates to kill cancer cells with nanoscale coordination polymers. Chemical communications (Cambridge, England), 2012, Mar-11, Volume: 48, Issue:21 Topics: Antineoplastic Agents; Calcium; Cell Line, Tumor; Cell Survival; Diphosphonates; Humans; Imidazoles; Lipid Bilayers; Nanoparticles; Pamidronate; Polymers; Zoledronic Acid	2012
A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. American journal of clinical oncology, 2012, Volume: 35, Issue:4 Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Incidence; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Neoplasm Staging; Neoplasms; Osteonecrosis; Pamidronate; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Zoledronic Acid	2012
Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study. Hospital practice (1995), 2012, Volume: 40, Issue:2 Topics: Bone Density Conservation Agents; Bone Neoplasms; Delphi Technique; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Nursing Staff, Hospital; Ontario; Pamidronate; Pharmacists; Quebec; Time Factors; Zoledronic Acid	2012
Radical surgical treatment of bisphosphonate related osteonecrosis of the jaw. Australian dental journal, 2012, Volume: 57, Issue:2 Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Maxillary Diseases; Maxillary Osteotomy; Middle Aged; Multiple Myeloma; Pamidronate; Peptides; Surgical Flaps; Tooth Extraction; Zoledronic Acid	2012
Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Nov-15, Volume: 18, Issue:22 Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Humans; Imidazoles; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Middle Aged; Multivariate Analysis; Pamidronate; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Zoledronic Acid	2012
Intravenous bisphosphonate-related osteonecrosis of the jaw: long-term follow-up of 109 patients. Oral surgery, oral medicine, oral pathology and oral radiology, 2013, Volume: 115, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Chi-Square Distribution; Comorbidity; Diabetes Mellitus; Diphosphonates; Disease Progression; DMF Index; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; New York City; Pamidronate; Risk Factors; Smoking; Zoledronic Acid	2013
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Chi-Square Distribution; Cisplatin; Cyclophosphamide; Deoxycytidine; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Hypercalcemia; Imidazoles; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Pamidronate; Parathyroid Hormone-Related Protein; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Taxoids; Young Adult; Zoledronic Acid	2012
Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Cancer Care Facilities; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Middle Aged; Pamidronate; Registries; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid	2013
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jun-20, Volume: 31, Issue:18 Topics: Administration, Intravenous; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Combined Modality Therapy; Diphosphonates; Drug Therapy, Combination; Fractures, Bone; Humans; Imidazoles; International Cooperation; Magnetic Resonance Imaging; Medical Oncology; Multiple Myeloma; Osteonecrosis; Outcome Assessment, Health Care; Pamidronate; Positron-Emission Tomography; Practice Guidelines as Topic; Radiotherapy; Tomography, X-Ray Computed; Zoledronic Acid	2013
Effects of bisphosphonates in combination with ionizing radiation and antioxidants on the growth of prostate and melanoma cells lines. Anticancer research, 2013, Volume: 33, Issue:8 Topics: Animals; Antioxidants; Apigenin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Melanoma; Mice; Pamidronate; Prostatic Neoplasms; Radiation, Ionizing; Skin Neoplasms; Zoledronic Acid	2013
Management of bisphosphonate-related osteonecrosis of the jaw with a platelet-rich fibrin membrane: technical report. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2014, Volume: 72, Issue:2 Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Blood Platelets; Diphosphonates; Fibrin; Humans; Imidazoles; Male; Membranes, Artificial; Multiple Myeloma; Pamidronate; Zoledronic Acid	2014
Sarcoglycans and integrins in bisphosphonate treatment: immunohistochemical and scanning electron microscopy study. Oncology reports, 2013, Volume: 30, Issue:6 Topics: Bone Neoplasms; Bone Resorption; Calcification, Physiologic; Cell Adhesion; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Humans; Imidazoles; Immunohistochemistry; Integrins; Jaw; Microscopy, Electron, Scanning; Mouth Mucosa; Osteonecrosis; Pamidronate; Sarcoglycans; Zoledronic Acid	2013
The cell cycle arrest and the anti-invasive effects of nitrogen-containing bisphosphonates are not mediated by DBF4 in breast cancer cells. Biochimie, 2014, Volume: 99 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphosphonates; Drug Screening Assays, Antitumor; Etidronic Acid; Female; Humans; Imidazoles; Inhibitory Concentration 50; Neoplasm Invasiveness; Pamidronate; Risedronic Acid; Zoledronic Acid	2014
Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:5 Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Pamidronate; Prostatic Neoplasms; Zoledronic Acid	2014
Effect of bisphosphonates on the rapidly growing male murine skeleton. Endocrinology, 2014, Volume: 155, Issue:4 Topics: Alendronate; Animals; Apoptosis; Biomechanical Phenomena; Bone and Bones; Bone Development; Bone Resorption; Chondrocytes; Clodronic Acid; Diphosphonates; Hypertrophy; Imidazoles; Male; Mice; Mice, Inbred C57BL; Pamidronate; Phenotype; X-Ray Microtomography; Zoledronic Acid	2014
A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2014, Volume: 42, Issue:6 Topics: Administration, Intravenous; Administration, Oral; Alendronate; Alveolar Process; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Early Diagnosis; Etidronic Acid; Female; Humans; Image Processing, Computer-Assisted; Imidazoles; Male; Mandible; Mandibular Diseases; Middle Aged; Osteolysis; Osteosclerosis; Pamidronate; Risedronic Acid; Risk Factors; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid	2014
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. European urology, 2014, Volume: 66, Issue:3 Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid	2014
In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes. Clinical oral investigations, 2015, Volume: 19, Issue:1 Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Chemotaxis; Clodronic Acid; Diphosphonates; Flow Cytometry; Granulocytes; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Neutrophils; Pamidronate; Phagocytosis; Respiratory Burst; Zoledronic Acid	2015
[Effects of four bisphosphonates on macrophage phagocytosis: quantitative measurement by flow cytometry using high-fluorescence particles and human monocytic cell line THP-1]. Rinsho byori. The Japanese journal of clinical pathology, 2014, Volume: 62, Issue:1 Topics: Alendronate; Apoptosis; Bone Density Conservation Agents; Cell Line; Diphosphonates; Flow Cytometry; Fluorescent Dyes; Humans; Imidazoles; Macrophages; Pamidronate; Phagocytosis; Zoledronic Acid	2014
Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study. Hospital practice (1995), 2014, Volume: 42, Issue:2 Topics: Aged; Ambulatory Care; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Canada; Costs and Cost Analysis; Cross-Sectional Studies; Diphosphonates; Equipment and Supplies; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Pamidronate; Prospective Studies; Prostatic Neoplasms; Time Factors; Zoledronic Acid	2014
Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma. Leukemia & lymphoma, 2015, Volume: 56, Issue:3 Topics: Aged; Bone Density Conservation Agents; Bone Resorption; Cohort Studies; Comparative Effectiveness Research; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pamidronate; Propensity Score; Proportional Hazards Models; Registries; Survival Rate; Veterans; Zoledronic Acid	2015
Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Aug-01, Volume: 20, Issue:15 Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Collagen Type I; Cytokines; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Osteonecrosis; Pamidronate; Peptides; Prognosis; Zoledronic Acid	2014
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:4 Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid	2015
PTH(1-34) Treatment Increases Bisphosphonate Turnover in Fracture Repair in Rats. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2015, Volume: 30, Issue:6 Topics: Animals; Carbon Isotopes; Diphosphonates; Femoral Fractures; Fracture Healing; Imidazoles; Isotope Labeling; Male; Pamidronate; Parathyroid Hormone; Rats; Rats, Wistar; Zoledronic Acid	2015
Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates. Journal of neurosurgery. Pediatrics, 2015, Volume: 15, Issue:3 Topics: Adolescent; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Humans; Imidazoles; Infant; Kaplan-Meier Estimate; Logistic Models; Male; Osteogenesis Imperfecta; Pamidronate; Platybasia; Retrospective Studies; Risedronic Acid; Skull Base; Zoledronic Acid	2015
The influence of geranylgeraniol on human oral keratinocytes after bisphosphonate treatment: An in vitro study. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2015, Volume: 43, Issue:5 Topics: Apoptosis; Bone Density Conservation Agents; Cell Culture Techniques; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Clodronic Acid; Diphosphonates; Diterpenes; Humans; Ibandronic Acid; Imidazoles; Keratinocytes; Mouth Mucosa; Pamidronate; Zoledronic Acid	2015
Bisphosphonates enhance bacterial adhesion and biofilm formation on bone hydroxyapatite. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2015, Volume: 43, Issue:6 Topics: Bacterial Adhesion; Bacteriological Techniques; Biocompatible Materials; Biofilms; Bone and Bones; Bone Density Conservation Agents; Clodronic Acid; Coated Materials, Biocompatible; Diphosphonates; Durapatite; Humans; Hydrogen Bonding; Imidazoles; Microscopy, Electron, Scanning; Pamidronate; Pseudomonas aeruginosa; Staphylococcus aureus; Static Electricity; Streptococcus mutans; X-Ray Microtomography; Zoledronic Acid	2015
Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2015, Volume: 30, Issue:12 Topics: Absorptiometry, Photon; Adolescent; Anthropometry; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium; Child; Child, Preschool; Collagen Type I; Collagen Type I, alpha 1 Chain; Densitometry; Diphosphonates; Female; Femoral Fractures; Follow-Up Studies; Fractures, Compression; Humans; Imidazoles; Infant; Infusions, Intravenous; Lumbar Vertebrae; Male; Mutation; Osteogenesis Imperfecta; Pamidronate; Scoliosis; Spinal Fusion; Tibial Fractures; Zoledronic Acid	2015
Quality and Outcomes of Treatment of Hypercalcemia of Malignancy. Cancer investigation, 2015, Volume: 33, Issue:8 Topics: Aged; Bone Neoplasms; Calcitonin; Diphosphonates; Diuretics; Female; Glucocorticoids; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Multivariate Analysis; Neoplasms; Pamidronate; Quality of Health Care; Treatment Outcome; Zoledronic Acid	2015
Hematopoietic Cell Transplantation in Patients with Medication-Related Osteonecrosis of the Jaws. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:2 Topics: Aged; Antineoplastic Agents; Diphosphonates; Female; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Jaw; Male; Middle Aged; Osteonecrosis; Pamidronate; Retrospective Studies; Staphylococcus aureus; Transplantation Conditioning; Zoledronic Acid	2016
Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study. Oncotarget, 2016, Oct-11, Volume: 7, Issue:41 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diphosphonates; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pamidronate; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome; Zoledronic Acid	2016
Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents. The oncologist, 2016, Volume: 21, Issue:4 Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Middle Aged; Pamidronate; Proportional Hazards Models; Retrospective Studies; Risk Factors; Zoledronic Acid	2016
[Bisphosphonate use and related pharmaceutical issues II]. Acta pharmaceutica Hungarica, 2016, Volume: 86, Issue:1 Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Confounding Factors, Epidemiologic; Diphosphonates; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hungary; Ibandronic Acid; Imidazoles; National Health Programs; Osteoporosis; Pamidronate; Retrospective Studies; Risedronic Acid; Zoledronic Acid	2016
Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw (MRONJ). Biochemical and biophysical research communications, 2016, Nov-04, Volume: 480, Issue:1 Topics: Animals; Antibodies, Monoclonal; Antigens, CD; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Pamidronate; Receptors, Antigen, T-Cell, gamma-delta; Semaphorins; T-Lymphocytes; Zoledronic Acid	2016
In Vitro Investigation of the Antimicrobial Effect of Three Bisphosphonates Against Different Bacterial Strains. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2018, Volume: 76, Issue:3 Topics: Anti-Infective Agents; Diphosphonates; Gram-Negative Bacteria; Gram-Positive Bacteria; Ibandronic Acid; Microbial Sensitivity Tests; Microbiota; Mouth; Pamidronate; Zoledronic Acid	2018
Efficacy and treatment costs of zoledronate versus pamidronate in paediatric osteoporosis. Archives of disease in childhood, 2018, Volume: 103, Issue:1 Topics: Administration, Intravenous; Bone Density; Bone Density Conservation Agents; Child; Diphosphonates; Female; Health Care Costs; Humans; Imidazoles; Male; Osteoporosis; Pamidronate; Retrospective Studies; Zoledronic Acid	2018
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary. Journal of oncology practice, 2017, Volume: 13, Issue:12 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Female; Humans; Medical Oncology; Ontario; Pain; Pamidronate; Societies, Medical; United States; Zoledronic Acid	2017
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Dec-10, Volume: 35, Issue:35 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid	2017
Lower incidence of fracture after IV bisphosphonates in girls with Rett syndrome and severe bone fragility. PloS one, 2017, Volume: 12, Issue:10 Topics: Adolescent; Adult; Bone Density; Bone Density Conservation Agents; Calcium; Child; Creatinine; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Incidence; Pamidronate; Rett Syndrome; Young Adult; Zoledronic Acid	2017
Clinical significance of increased serum levels of FGF-23 in fibrous dysplasia. Medicina clinica, 2018, 07-23, Volume: 151, Issue:2 Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density Conservation Agents; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibrous Dysplasia of Bone; Humans; Male; Middle Aged; Osteomalacia; Pamidronate; Phosphorus; Reference Values; Young Adult; Zoledronic Acid	2018
Acquired resistance to pamidronate treated effectively with zoledronate in juvenile Paget's disease. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2018, Volume: 29, Issue:6 Topics: Bone Density Conservation Agents; Drug Resistance; Drug Substitution; Gene Deletion; Humans; Infant; Male; Osteitis Deformans; Osteoprotegerin; Pamidronate; Radiography; Zoledronic Acid	2018
Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention. Oral surgery, oral medicine, oral pathology and oral radiology, 2018, Volume: 125, Issue:5 Topics: Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Incidence; Indoles; Ipilimumab; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Pamidronate; Pyrroles; Retrospective Studies; Sunitinib; Zoledronic Acid	2018
Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma. Journal of the National Comprehensive Cancer Network : JNCCN, 2019, Volume: 17, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Medicare; Multiple Myeloma; Pamidronate; Practice Guidelines as Topic; Retrospective Studies; SEER Program; Treatment Outcome; United States; Zoledronic Acid	2019
Evaluation of effects of radiation therapy combined with either pamidronate or zoledronate on canine osteosarcoma cells. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire, 2019, Volume: 83, Issue:1 Topics: Animals; Bone Density Conservation Agents; Cell Line, Tumor; Cell Survival; Dogs; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Osteosarcoma; Pamidronate; Tumor Stem Cell Assay; Zoledronic Acid	2019
Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer. Journal of radiation research, 2020, May-22, Volume: 61, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Denosumab; Female; Humans; Middle Aged; Neoplasm Metastasis; Osteolysis; Pamidronate; Prognosis; Radiotherapy, Conformal; Retrospective Studies; Spine; Zoledronic Acid	2020
Effect of timing of bisphosphonate administration on canine osteosarcoma cells undergoing radiation therapy. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire, 2020, Volume: 84, Issue:3 Topics: Animals; Bone Density Conservation Agents; Cell Line, Tumor; Cell Survival; Dog Diseases; Dogs; Drug Administration Schedule; Osteosarcoma; Pamidronate; Zoledronic Acid	2020
Tissue-Nonspecific Alkaline Phosphatase (TNAP) as the Enzyme Involved in the Degradation of Nucleotide Analogues in the Ligand Docking and Molecular Dynamics Approaches. Biomolecules, 2021, 07-27, Volume: 11, Issue:8 Topics: Adenosine Triphosphate; Alendronate; Alkaline Phosphatase; Computational Biology; Diphosphates; Diphosphonates; Enzymes; Humans; Hydrogen Bonding; Ligands; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Pamidronate; Phosphates; Protein Conformation; Thermodynamics; Zoledronic Acid	2021
One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022, Volume: 30, Issue:9 Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Humans; Pamidronate; Quality of Life; Risk Assessment; Zoledronic Acid	2022
Comparative Treatment Persistence with Bone-Targeting Agents Among Asian Patients with Bone Metastases from Solid Tumors: A Multinational Retrospective Cohort Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2022, Volume: 36, Issue:3 Topics: Bone Density Conservation Agents; Bone Neoplasms; Cohort Studies; Denosumab; Diphosphonates; Humans; Male; Pamidronate; Retrospective Studies; Zoledronic Acid	2022
Pamidronate versus zoledronic acid for the treatment of multiple myeloma-related hypercalcemia. Kidney international, 2022, Volume: 101, Issue:5 Topics: Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Pamidronate; Zoledronic Acid	2022
Medication-Related Osteonecrosis of the Jaws in the Pediatric Population. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2022, Volume: 80, Issue:10 Topics: Adolescent; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Child; Child, Preschool; Denosumab; Diphosphonates; Female; Humans; Immunosuppressive Agents; Infant; Infant, Newborn; Jaw; Male; Osteonecrosis; Pamidronate; Retrospective Studies; Zoledronic Acid	2022
Bisphosphonate type-dependent cell viability suppressive effects of carbon nanohorn-calcium phosphate-bisphosphonate nanocomposites. Biomaterials science, 2022, Oct-11, Volume: 10, Issue:20 Topics: Animals; Bone Neoplasms; Bone Resorption; Calcium Phosphates; Carbon; Cell Survival; Diphosphonates; Drug Carriers; Ibandronic Acid; Mice; Nanocomposites; Osteoclasts; Pamidronate; Reactive Oxygen Species; Zoledronic Acid	2022